

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1639MLS

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 20:47:15 ON 23 SEP 2004
FILE 'REGISTRY' ENTERED AT 20:47:15 ON 23 SEP 2004
COPYRIGHT (C) 2004 American Chemical Society (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.10	2.31

=> d his

(FILE 'HOME' ENTERED AT 20:38:41 ON 23 SEP 2004)

FILE 'REGISTRY' ENTERED AT 20:39:05 ON 23 SEP 2004

L1 STRUCTURE UPLOADED
L2 50 S SAM L1

=> s l1 full

FULL SEARCH INITIATED 20:47:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 491947 TO ITERATE

81.3% PROCESSED 400000 ITERATIONS 62637 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.03

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 491947 TO 491947
PROJECTED ANSWERS: 76203 TO 77867

L3 62637 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	157.52	157.73

FILE 'CAPLUS' ENTERED AT 20:48:04 ON 23 SEP 2004 .
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

strictly prohibited.

FILE COVERS 1907 - 23 Sep 2004 VOL 141 ISS 13
FILE LAST UPDATED: 22 Sep 2004 (20040922/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s 13 and receptor

23107 L3

571186 RECEPTOR

L4 771 L3 AND RECEPTOR

=> s 14 and ligand

264845 LIGAND

L5 73 L4 AND LIGAND

=> t ti 15 1-50

L5 ANSWER 1 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN

TI Synthesis, in vitro pharmacology, structure-activity relationships, and
pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-
dicarboxylic acid derivatives as potent and selective group II
metabotropic glutamate **receptor** antagonists

L5 ANSWER 2 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN

TI [3H]A-317491, a novel high-affinity non-nucleotide antagonist that
specifically labels human P2X2/3 and P2X3 receptors

L5 ANSWER 3 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN

TI Dye-Labeled Benzodiazepines: Development of Small Ligands for
Receptor Binding Studies Using Fluorescence Correlation
Spectroscopy

L5 ANSWER 4 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN

TI Fluorescent ligands and measuring of binding of samples to androgen
receptor

L5 ANSWER 5 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN

TI Preparation of 4-(phenylpiperazinylmethyl)benzamides for treatment of pain
or gastrointestinal disorders

L5 ANSWER 6 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN

TI Ligands for the peroxisome proliferator-activated **receptor**

L5 ANSWER 7 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN

TI Preparation of a novel diphosphine-palladium macrocyclic complex
possessing a molecular recognition site. Oxidative addition studies

L5 ANSWER 8 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN

TI Design and Synthesis of Novel Dimeric Morphinan Ligands for κ and
 μ Opioid Receptors

L5 ANSWER 9 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN

TI Rational Design and Synthesis of Androgen **Receptor**-Targeted
Nonsteroidal Anti-Androgen Ligands for the Tumor-Specific Delivery of a
Doxorubicin-Formaldehyde Conjugate

L5 ANSWER 10 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN

TI 2', 3'-O-(2,4,6, trinitrophenyl)-ATP and A-317491 are competitive
antagonists at a slowly desensitizing chimeric human P2X3 **receptor**

L5 ANSWER 11 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of pyridones as modulators of nuclear receptors, including liver X **receptor** (LXR).

L5 ANSWER 12 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Novel fluorescence based **receptor** binding assay method for receptors lacking **ligand** conjugates with preserved affinity: Study on estrogen **receptor** α

L5 ANSWER 13 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of novel bivalent multi-binding phenolic amino compounds as β 2-adrenergic **receptor** agonists

L5 ANSWER 14 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI A novel strapped porphyrin **receptor** for molecular recognition

L5 ANSWER 15 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Synthetic Inhibitors of Proline-Rich **Ligand**-Mediated Protein-Protein Interaction: Potent Analogs of UCS15A

L5 ANSWER 16 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of piperidino cannabinoid **receptor** ligands

L5 ANSWER 17 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of benzotriazepines as gastrin and cholecystokinin **receptor** ligands for treating gastrointestinal disorders

L5 ANSWER 18 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI cDNAs encoding human olfactory cyclic nucleotide gated (CNG) channel subunits for use in enhancing smell receptors

L5 ANSWER 19 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of [1,2']bipyrazinyl 5-HT2 **receptor** ligands for treatment of sexual dysfunction

L5 ANSWER 20 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Exponential pattern recognition-based cellular targeting, compositions, methods and anticancer applications

L5 ANSWER 21 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Treatment of respiratory and lung diseases with antisense oligonucleotides and a bronchodilating agent

L5 ANSWER 22 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Treatment of respiratory and lung diseases with antisense oligonucleotides and a bronchodilating agent

L5 ANSWER 23 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Synthesis and Investigation of New Macrocyclic Diphosphine-Palladium(0) Complexes Based on the Barbiturate Binding **Receptor**

L5 ANSWER 24 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Anion-Templated Rotaxane Formation

L5 ANSWER 25 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABAA **receptor**

L5 ANSWER 26 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of nicotinilide-N-oxides as G-protein-coupled **receptor** antagonist for the treatment of inflammation due to

neutrophil chemotaxis

- L5 ANSWER 27 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Environment and mobility of a series of fluorescent reporters at the amino terminus of structurally related peptide agonists and antagonists bound to the cholecystokinin **receptor**
- L5 ANSWER 28 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of naphthalene derivatives as cannabinoid CB1 **receptor** ligands.
- L5 ANSWER 29 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of novel multi-binding phenolic compounds as β 2-adrenergic **receptor** agonists
- L5 ANSWER 30 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Comparative binding energy (COMBINE) analysis of human neutrophil elastase inhibition by pyridone-containing trifluoromethylketones
- L5 ANSWER 31 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Pharmacological analysis of CCK2 **receptor** ligands using COS-7 and SK-N-MC cells, expressing the human CCK2 **receptor**
- L5 ANSWER 32 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation and formulation of imidazoles as gastrin and cholecystokinin **receptor** ligands for treatment of gastrointestinal disorders
- L5 ANSWER 33 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation and pharmaceutical compositions of gastrin/cholecystokinin **receptor** ligands with proton pump inhibitors
- L5 ANSWER 34 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Analysis of fluorescently labeled substance P analogs: binding, imaging and **receptor** activation
- L5 ANSWER 35 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Validation of flow cytometric competitive binding protocols and characterization of fluorescently labeled ligands
- L5 ANSWER 36 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Therapeutic uses of PPAR mediators as ABC-1 expression modulators, and preparation thereof
- L5 ANSWER 37 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors
- L5 ANSWER 38 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Synthesis and characterization of new aromatic tweezers and complex formation with tropylium ion in 1,2-dichloroethane
- L5 ANSWER 39 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of 4-(arylhydroxyethylaminoethyl)phenylaminohydroxyethylbenzenes and related compounds as β 2 adrenergic **receptor** agonists and partial agonists.
- L5 ANSWER 40 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Nonpeptide cholecystokinin-2 **receptor** agonists
- L5 ANSWER 41 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of novel multibinding phenolic compounds as β 2-adrenergic **receptor** agonists

L5 ANSWER 42 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
 TI Preparation of inositol 1,4,5-triphosphate derivatives as IP3 **receptor** ligands

L5 ANSWER 43 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
 TI Use of triazolopyridazine GABAA **receptor** ligands for treating premenstrual syndrome

L5 ANSWER 44 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
 TI Tri-aryl acid derivatives as PPAR **receptor** ligands

L5 ANSWER 45 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
 TI Preparation gastrin and cholecystokinin **receptor** ligands

L5 ANSWER 46 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
 TI Estimation of **Receptor-Ligand** Interactions by the Use of a Two-Marker System in Affinity Capillary Electrophoresis

L5 ANSWER 47 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
 TI Chiral, metal templated self-assembly

L5 ANSWER 48 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
 TI Preparation of multibinding piperidinyllindole derivatives as therapeutic agents that modulate 5-HT receptors

L5 ANSWER 49 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
 TI Dual avb3 and metastasis-associated **receptor** ligands

L5 ANSWER 50 OF 73 CAPLUS COPYRIGHT 2004 ACS on STN
 TI Chemical probes that differentially modulate peroxisome proliferator-activated **receptor** α and BLTR, nuclear and cell surface receptors for leukotriene B4

=> d scan 15

L5 73 ANSWERS CAPLUS COPYRIGHT 2004 ACS on STN
 CC 1-6 (Pharmacology)
 Section cross-reference(s): 21

TI Rational Design and Synthesis of Androgen **Receptor**-Targeted Nonsteroidal Anti-Androgen Ligands for the Tumor-Specific Delivery of a Doxorubicin-Formaldehyde Conjugate

ST androgen **receptor** prostate tumor nonsteroidal antiandrogen doxorubicin formaldehyde conjugate

IT Androgens
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antiandrogens; rational design and synthesis of androgen **receptor**-targeted nonsteroidal anti-androgen ligands for tumor-specific delivery of a doxorubicin-formaldehyde conjugate)

IT Antitumor agents
 Drug delivery systems
 Drug design
 Human
 Prostate gland, neoplasm
 (rational design and synthesis of androgen **receptor**-targeted nonsteroidal anti-androgen ligands for tumor-specific delivery of a doxorubicin-formaldehyde conjugate)

IT Androgen receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (rational design and synthesis of androgen **receptor**-targeted nonsteroidal anti-androgen ligands for tumor-specific delivery of a

doxorubicin-formaldehyde conjugate)

IT 636595-46-5P
 RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (rational design and synthesis of androgen **receptor**-targeted nonsteroidal anti-androgen ligands for tumor-specific delivery of a doxorubicin-formaldehyde conjugate)

IT 636595-77-2P 636595-79-4P 636595-81-8P
 636595-90-9P 636595-92-1P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (rational design and synthesis of androgen **receptor**-targeted nonsteroidal anti-androgen ligands for tumor-specific delivery of a doxorubicin-formaldehyde conjugate)

IT 636595-44-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (rational design and synthesis of androgen **receptor**-targeted nonsteroidal anti-androgen ligands for tumor-specific delivery of a doxorubicin-formaldehyde conjugate)

IT 65-45-2, Salicylamide 13311-84-7, Flutamide
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (rational design and synthesis of androgen **receptor**-targeted nonsteroidal anti-androgen ligands for tumor-specific delivery of a doxorubicin-formaldehyde conjugate)

IT 636595-94-3
 RL: PRP (Properties)
 (rational design and synthesis of androgen **receptor**-targeted nonsteroidal anti-androgen ligands for tumor-specific delivery of a doxorubicin-formaldehyde conjugate)

IT 76143-20-9P 636595-48-7P 636595-54-5P 636595-56-7P
 636595-58-9P 636595-61-4P 636595-63-6P 636595-66-9P 636595-74-9P
 636595-83-0P 636595-85-2P 636595-86-3P 636595-88-5P
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (rational design and synthesis of androgen **receptor**-targeted nonsteroidal anti-androgen ligands for tumor-specific delivery of a doxorubicin-formaldehyde conjugate)

IT 636595-41-0P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (rational design and synthesis of androgen **receptor**-targeted nonsteroidal anti-androgen ligands for tumor-specific delivery of a doxorubicin-formaldehyde conjugate)

IT 77-71-4 36894-69-6, Labetalol 194853-86-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (rational design and synthesis of androgen **receptor**-targeted nonsteroidal anti-androgen ligands for tumor-specific delivery of a doxorubicin-formaldehyde conjugate)

IT 636595-50-1P 636595-52-3P 636595-68-1P 636595-71-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (rational design and synthesis of androgen **receptor**-targeted nonsteroidal anti-androgen ligands for tumor-specific delivery of a doxorubicin-formaldehyde conjugate)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> d his

(FILE 'HOME' ENTERED AT 20:38:41 ON 23 SEP 2004)

FILE 'REGISTRY' ENTERED AT 20:39:05 ON 23 SEP 2004

L1 STRUCTURE UPLOADED
L2 50 S SAM L1
L3 62637 S L1 FULL

FILE 'CAPLUS' ENTERED AT 20:48:04 ON 23 SEP 2004

L4 771 S L3 AND RECEPTOR
L5 73 S L4 AND LIGAND

=> s l5 and (divalent or multivalent or dimeric or multimeric or multipartite or dipartite)

63043 DIVALENT
9338 MULTIVALENT
34512 DIMERIC
3637 MULTIMERIC
230 MULTIPARTITE
2 DIPARTITE

L6 5 L5 AND (DIVALENT OR MULTIVALENT OR DIMERIC OR MULTIMERIC OR MULTIPARTITE OR DIPARTITE)

=> t ti l6 1-5

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
TI Design and Synthesis of Novel **Dimeric** Morphinan Ligands for κ and μ Opioid Receptors

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of novel bivalent multi-binding phenolic amino compounds as β 2-adrenergic **receptor** agonists

L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of novel multi-binding phenolic compounds as β 2-adrenergic **receptor** agonists

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of novel multibinding phenolic compounds as β 2-adrenergic **receptor** agonists

L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of multibinding piperidinyllindole derivatives as therapeutic agents that modulate 5-HT receptors

=> d ibib abs l6 1-5

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:840480 CAPLUS
DOCUMENT NUMBER: 140:42322
TITLE: Design and Synthesis of Novel **Dimeric** Morphinan Ligands for κ and μ Opioid Receptors
AUTHOR(S): Neumeyer, John L.; Zhang, Ao; Xiong, Wennan; Gu, Xiao-Hui; Hilbert, James E.; Knapp, Brian I.; Negus, S. Stevens; Mello, Nancy K.; Bidlack, Jean M.
CORPORATE SOURCE: Alcohol and Drug Abuse Research Center, Harvard Medical School, McLean Hospital, Belmont, MA, 02478, USA
SOURCE: Journal of Medicinal Chemistry (2003), 46(24), 5162-5170

PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:42322
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A novel series of morphinans were synthesized, and their binding affinity at and functional selectivity for μ , δ , and κ opioid receptors were evaluated. These **dimeric** ligands can be viewed as **dimeric** morphinans, which were formed by coupling two identical morphinan pharmacophores (cyclorphan or MCL 101) with varying connecting spacers. Ligands with alkyl spacers on the nitrogen position and ligands in which the two morphinan pharmacophores were coupled by ether moieties at the 3-hydroxyl positions showed significant decrease in affinity at all three opioid receptors. An improvement in the affinity was achieved by introducing an ester moiety as the spacer in the **dimeric** morphinans. It was observed that the affinity of these ligands was sensitive to the character and length of the spacer. I (X = (CH₂)₂) (MCL-139) with a 4-carbon ester spacer, I (X = (CH₂)₈) (MCL-144) containing a 10-carbon spacer, and (X = CH:CH) with the conformationally constrained fumaryl spacer were the most potent ligands in this series, displaying excellent affinities at μ and κ receptors (K_i = 0.09-0.2 nM at μ and K_i = 0.078-0.049 nM at κ), which were comparable to the parent compound II, a compound containing only one morphinan

pharmacophore and a long-chain ester group, had affinity at both μ and κ receptors almost identical to that of the parent **ligand**. In the [35S]GTP γ S binding assay, ligands I (X = (CH₂)₂, (CH₂)₈, CH:CH) and their parent morphinans stimulated [35S]GTP γ S binding mediated by the μ and κ receptors. I (X = (CH₂)₂, (CH₂)₈) were full κ agonists and partial μ agonists, while I (X = CH:CH) was a partial agonist at both μ and κ receptors. These novel ligands, as well as their interesting pharmacol. properties, will serve as the basis for our continuing investigation of the **dimeric** ligands as potential probes for the pharmacotherapy of cocaine abuse and may also open new avenues for the characterization of opioid receptors.


REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:545792 CAPLUS
DOCUMENT NUMBER: 139:100926
TITLE: Preparation of novel bivalent multi-binding phenolic amino compounds as β 2-adrenergic **receptor** agonists
INVENTOR(S): Choi, Seok-Ki; Moran, Edmund J.
PATENT ASSIGNEE(S): Theravance, Inc., USA
SOURCE: U.S., 63 pp., Cont. of U.S. Ser. No. 323,939, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

US 6593497	B1	20030715	US 2000-504761	20000214
PRIORITY APPLN. INFO.:			US 1999-323939	B1 19990602
OTHER SOURCE(S):	MARPAT 139:100926			
GI				



AB Novel bivalent, multi-binding, phenolic amine compds. IpXq (I) are disclosed [wherein: L = β -hydroxy- β -arylethylamine-based ligand, linked at carbon or nitrogen; X = specified, optionally repeating linker; p = 2-10; q = 1-20]. Compds. I are β 2-adrenergic **receptor** agonists (no data), and are therefore useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis, and the like. I are also useful in the treatment of nervous system injury and premature labor. Claims cover, in particular, compds. Ar1-CH(OH)CH2-NH-X-NH-CH2CH(OH)-Ar2 [where: Ar1, Ar2 = certain (un)substituted Ph groups; X = (CH2)6-O-[(CH2)6-O]0-9(CH2)6]. Ten compound synthetic examples are given for II [X = various monomeric, polymeric, and oligomeric (poly)oxyalkylene chains]. Compds. II were prepared from 5-acetylsalicylic acid Me ester via: (1) oxidation to α,α -dihydroxy-4-hydroxy-3-(methoxycarbonyl)acetophenone using HBr in DMSO, and (2) condensation of the latter with various diamines and borane reduction of the formed intermediate imines. In addition, combinatorial arrays of **multimeric** ligands and methods of assaying the **multimeric** ligand libraries for β 2-adrenergic agonist activity are embodied by the invention. Formulations for capsules, tablets, a dry powder inhaler, suppositories, suspensions, and topical forms are described.

REFERENCE COUNT: 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:354101 CAPLUS
 DOCUMENT NUMBER: 136:355062
 TITLE: Preparation of novel multi-binding phenolic compounds as β 2-adrenergic **receptor** agonists
 INVENTOR(S): Moran, Edmund J.; Griffin, John H.; Choi, Seok-ki
 PATENT ASSIGNEE(S): Theravance, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 92 pp., Cont. of U.S. Ser. No. 323,943.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 31
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002055651	A1	20020509	US 2001-934982	20010821

US 6683115	B2	20040127		
US 6541669	B1	20030401	US 1999-323943	19990602
CA 2318894	AA	19991216	CA 1999-2318894	19990604
AU 9945435	A1	19991230	AU 1999-45435	19990604
EP 1003540	A1	20000531	EP 1999-928344	19990604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002517457	T2	20020618	JP 2000-553099	19990604
CA 2318055	AA	19991216	CA 1999-2318055	19990607
CA 2318286	AA	19991216	CA 1999-2318286	19990607
CA 2319068	AA	19991216	CA 1999-2319068	19990607
CA 2319159	AA	19991216	CA 1999-2319159	19990607
CA 2319175	AA	19991216	CA 1999-2319175	19990607
CA 2319496	AA	19991216	CA 1999-2319496	19990607
CA 2319751	AA	19991216	CA 1999-2319751	19990607
CA 2319756	AA	19991216	CA 1999-2319756	19990607
CA 2321170	AA	19991216	CA 1999-2321170	19990607
CA 2321273	AA	19991216	CA 1999-2321273	19990607
AU 9944234	A1	19991230	AU 1999-44234	19990607
AU 9944265	A1	19991230	AU 1999-44265	19990607
AU 9945491	A1	19991230	AU 1999-45491	19990607
AU 9945520	A1	19991230	AU 1999-45520	19990607
AU 9946727	A1	19991230	AU 1999-46727	19990607
AU 9946751	A1	19991230	AU 1999-46751	19990607
AU 9946752	A1	19991230	AU 1999-46752	19990607
AU 9946754	A1	19991230	AU 1999-46754	19990607
EP 1019360	A1	20000719	EP 1999-930123	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1080080	A1	20010307	EP 1999-930158	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1083917	A1	20010321	EP 1999-927291	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1083893	A1	20010321	EP 1999-927331	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1083888	A1	20010321	EP 1999-928425	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1085887	A2	20010328	EP 1999-928349	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1085870	A2	20010328	EP 1999-930157	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1094826	A1	20010502	EP 1999-930156	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1100519	A1	20010523	EP 1999-930155	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1107753	A1	20010620	EP 1999-928457	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002517420	T2	20020618	JP 2000-553004	19990607
JP 2002517459	T2	20020618	JP 2000-553102	19990607
JP 2002517463	T2	20020618	JP 2000-553110	19990607
CA 2319497	AA	19991216	CA 1999-2319497	19990608
CA 2319643	AA	19991216	CA 1999-2319643	19990608
CA 2319651	AA	19991216	CA 1999-2319651	19990608



CA 2320926	AA	19991216	CA 1999-2320926	19990608
CA 2321120	AA	19991216	CA 1999-2321120	19990608
CA 2321152	AA	19991216	CA 1999-2321152	19990608
CA 2319650	AA	19991229	CA 1999-2319650	19990608
AU 9943368	A1	19991230	AU 1999-43368	19990608
AU 9943376	A1	19991230	AU 1999-43376	19990608
AU 9946747	A1	19991230	AU 1999-46747	19990608
AU 9952039	A1	19991230	AU 1999-52039	19990608
AU 9946776	A1	20000110	AU 1999-46776	19990608
EP 1082289	A1	20010314	EP 1999-930185	19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1083921	A1	20010321	EP 1999-955430	19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1085889	A2	20010328	EP 1999-928451	19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1085847	A2	20010328	EP 1999-928520	19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1085868	A1	20010328	EP 1999-930150	19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1085894	A1	20010328	EP 1999-937155	19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1102597	A1	20010530	EP 1999-955431	19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002517442	T2	20020618	JP 2000-553068	19990608
US 6288055	B1	20010911	US 2000-499476	20000207
ZA 2000003475	A	20011011	ZA 2000-3475	20000711
ZA 2000004083	A	20011112	ZA 2000-4083	20000810
ZA 2000004085	A	20011112	ZA 2000-4085	20000810
ZA 2000004087	A	20011113	ZA 2000-4087	20000810
ZA 2000004084	A	20011119	ZA 2000-4084	20000810
ZA 2000004561	A	20011130	ZA 2000-4561	20000831
ZA 2000004565	A	20011130	ZA 2000-4565	20000831
US 2003087306	A1	20030508	US 2001-15534	20011213
US 2003087307	A1	20030508	US 2002-108945	20020328

PRIORITY APPLN. INFO.:

US 1998-88466P	P	19980608
US 1998-92938P	P	19980715
US 1999-323943	A1	19990602
WO 1999-US11786	W	19990604
US 1999-327044	B1	19990607
WO 1999-US11803	W	19990607
WO 1999-US11805	W	19990607
WO 1999-US12669	W	19990607
WO 1999-US12673	W	19990607
WO 1999-US12727	W	19990607
WO 1999-US12728	W	19990607
WO 1999-US12730	W	19990607
WO 1999-US12731	W	19990607
WO 1999-US12778	W	19990607
WO 1999-US12782	W	19990607
US 1999-327904	B1	19990608
WO 1999-US12626	W	19990608
WO 1999-US12770	W	19990608
WO 1999-US12876	W	19990608
WO 1999-US12907	W	19990608
WO 1999-US12989	W	19990608

WO 1999-US12994	W 19990608
WO 1999-US12995	W 19990608
US 1999-457618	B1 19991208
US 2000-493462	B1 20000128
US 2000-637899	A1 20000814

OTHER SOURCE(S): MARPAT 136:355062
GI



AB Methods for preparing novel multibinding phenolic compds., LpXq [where L = a **ligand** capable of binding to a β 2-adrenergic **receptor**; X = a linker; p = 2-10; q = 1-20], which serve as β 2-adrenergic **receptor** agonists, are disclosed. Preferred ligands are of formula I [R1 = H, (un)substituted alkyl, or a bond linking **ligand** to linker; R2 = H, aralkyl, acyl, (un)substituted alkyl, cycloalkyl or a bond linking **ligand** to linker; W = bond, (un)substituted alkylene wherein one or more carbon atoms is optionally replaced by NR3, O, S, SO, SO2, CO, P-alkyl, PO2, OP(O)O or the alkylene optionally links the **ligand** to a linker with provisions; R3 = H, alkyl, acyl, or bond linking **ligand** to linker; X = aryl, heteroaryl, heterocyclyl and (un)substituted cycloalkyl wherein each X optionally links the **ligand** to the linker]. II was prepared from α,α -dihydroxy-4-hydroxy-3-methoxycarbonylacetophenone via condensation with trans-1,4-diaminocyclohexane with subsequent reduction of intermediate imine. In addition, combinatorial arrays of **multimeric** ligands and methods of assaying the **multimeric** ligands are embodied by the invention. As β 2-adrenergic **receptor** agonists, the compds. are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis (no data). The title compds. are also useful in the treatment of nervous system injuries and premature labor. Formulations for capsules, tablets, dry power inhaler, suppositories and suspensions are described.

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:102476 CAPLUS
 DOCUMENT NUMBER: 134:131310
 TITLE: Preparation of novel multibinding phenolic compounds
 as β 2-adrenergic **receptor** agonists

INVENTOR(S): Griffin, John H.; Moran, Edmund J.; Choi, Seok-Ki
PATENT ASSIGNEE(S): Advanced Medicine, Inc., USA
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 31
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9964035	A1	19991216	WO 1999-US11804	19990607
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6362371	B1	20020326	US 1999-323937	19990602
CA 2318894	AA	19991216	CA 1999-2318894	19990604
WO 9964031	A1	19991216	WO 1999-US11786	19990604
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9945435	A1	19991230	AU 1999-45435	19990604
EP 1003540	A1	20000531	EP 1999-928344	19990604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002517457	T2	20020618	JP 2000-553099	19990604
CA 2318055	AA	19991216	CA 1999-2318055	19990607
CA 2318192	AA	19991216	CA 1999-2318192	19990607
CA 2318286	AA	19991216	CA 1999-2318286	19990607
CA 2319068	AA	19991216	CA 1999-2319068	19990607
CA 2319159	AA	19991216	CA 1999-2319159	19990607
CA 2319175	AA	19991216	CA 1999-2319175	19990607
CA 2319496	AA	19991216	CA 1999-2319496	19990607
CA 2319751	AA	19991216	CA 1999-2319751	19990607
CA 2319756	AA	19991216	CA 1999-2319756	19990607
CA 2321170	AA	19991216	CA 1999-2321170	19990607
CA 2321273	AA	19991216	CA 1999-2321273	19990607
WO 9964034	A1	19991216	WO 1999-US11803	19990607
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 9963930	A2	19991216	WO 1999-US11805	19990607
WO 9963930	A3	20000127		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				

DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
 KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
 MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
 TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 WO 9963983 A1 19991216 WO 1999-US12669 19990607
 W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
 DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
 KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
 MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
 TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 WO 9964038 A1 19991216 WO 1999-US12673 19990607
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
 DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
 JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
 MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
 TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 WO 9964041 A1 19991216 WO 1999-US12727 19990607
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
 DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
 JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
 MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
 TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 WO 9964042 A1 19991216 WO 1999-US12728 19990607
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
 DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
 JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
 MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
 TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 WO 9963933 A2 19991216 WO 1999-US12730 19990607
 WO 9963933 A3 20000203
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
 DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
 JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
 MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
 TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 WO 9964000 A1 19991216 WO 1999-US12731 19990607
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
 DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,

JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
 MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
 TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 WO 9963993 A1 19991216 WO 1999-US12778 19990607
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
 DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
 JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
 MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
 TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 WO 9963996 A1 19991216 WO 1999-US12782 19990607
 W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
 DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
 KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
 MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
 TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BJ, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 AU 9944234 A1 19991230 AU 1999-44234 19990607
 AU 9944265 A1 19991230 AU 1999-44265 19990607
 AU 9945491 A1 19991230 AU 1999-45491 19990607
 AU 9945520 A1 19991230 AU 1999-45520 19990607
 AU 9946727 A1 19991230 AU 1999-46727 19990607
 AU 9946751 A1 19991230 AU 1999-46751 19990607
 AU 9946752 A1 19991230 AU 1999-46752 19990607
 AU 9946754 A1 19991230 AU 1999-46754 19990607
 AU 9948181 A1 19991230 AU 1999-48181 19990607
 AU 750366 B2 20020718
 EP 1019360 A1 20000719 EP 1999-930123 19990607
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 EP 1019075 A1 20000719 EP 1999-931748 19990607
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 EP 1080080 A1 20010307 EP 1999-930158 19990607
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 EP 1083917 A1 20010321 EP 1999-927291 19990607
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 EP 1083893 A1 20010321 EP 1999-927331 19990607
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 EP 1083888 A1 20010321 EP 1999-928425 19990607
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 EP 1085887 A2 20010328 EP 1999-928349 19990607
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 EP 1085870 A2 20010328 EP 1999-930157 19990607
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 EP 1094826 A1 20010502 EP 1999-930156 19990607

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

EP 1100519 A1 20010523 EP 1999-930155 19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

EP 1107753 A1 20010620 EP 1999-928457 19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

TR 200003650 T2 20010821 TR 2000-200003650 19990607
BR 9910832 A 20011016 BR 1999-10832 19990607
JP 2002517420 T2 20020618 JP 2000-553004 19990607
JP 2002517459 T2 20020618 JP 2000-553102 19990607
JP 2002517460 T2 20020618 JP 2000-553103 19990607
JP 2002517463 T2 20020618 JP 2000-553110 19990607
SG 93205 A1 20021217 SG 1999-2843 19990607
CA 2319497 AA 19991216 CA 1999-2319497 19990608
CA 2319643 AA 19991216 CA 1999-2319643 19990608
CA 2319651 AA 19991216 CA 1999-2319651 19990608
CA 2320926 AA 19991216 CA 1999-2320926 19990608
CA 2321120 AA 19991216 CA 1999-2321120 19990608
CA 2321152 AA 19991216 CA 1999-2321152 19990608
WO 9963999 A1 19991216 WO 1999-US12626 19990608

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 9963936 A2 19991216 WO 1999-US12770 19990608
WO 9963936 A3 20000203

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 9964052 A1 19991216 WO 1999-US12876 19990608

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 9964053 A1 19991216 WO 1999-US12907 19990608

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM



RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 9964055	A1	19991216	WO 1999-US12994	19990608
WO 9964055	C2	20020829		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
WO 9963944	A2	19991216	WO 1999-US12995	19990608
WO 9963944	A3	20000210		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2319650	AA	19991229	CA 1999-2319650	19990608
WO 9966944	A1	19991229	WO 1999-US12989	19990608
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9943368	A1	19991230	AU 1999-43368	19990608
AU 9943376	A1	19991230	AU 1999-43376	19990608
AU 9946747	A1	19991230	AU 1999-46747	19990608
AU 9952039	A1	19991230	AU 1999-52039	19990608
AU 9946776	A1	20000110	AU 1999-46776	19990608
EP 1082289	A1	20010314	EP 1999-930185	19990608
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
EP 1083921	A1	20010321	EP 1999-955430	19990608
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
EP 1085889	A2	20010328	EP 1999-928451	19990608
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
EP 1085847	A2	20010328	EP 1999-928520	19990608
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
EP 1085868	A1	20010328	EP 1999-930150	19990608
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
EP 1085894	A1	20010328	EP 1999-937155	19990608
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
EP 1102597	A1	20010530	EP 1999-955431	19990608
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
SG 81994	A1	20010724	SG 1999-2713	19990608
SG 83720	A1	20011016	SG 1999-2715	19990608
SG 83721	A1	20011016	SG 1999-2717	19990608

US 6355805	B1	20020312	US 1999-328192	19990608
JP 2002517442	T2	20020618	JP 2000-553068	19990608
US 6288055	B1	20010911	US 2000-499476	20000207
ZA 2000003475	A	20011011	ZA 2000-3475	20000711
ZA 2000004083	A	20011112	ZA 2000-4083	20000810
ZA 2000004085	A	20011112	ZA 2000-4085	20000810
ZA 2000004087	A	20011113	ZA 2000-4087	20000810
ZA 2000004084	A	20011119	ZA 2000-4084	20000810
ZA 2000004561	A	20011130	ZA 2000-4561	20000831
ZA 2000004565	A	20011130	ZA 2000-4565	20000831
US 6713651	B1	20040330	US 2000-674451	20001101
NO 2000006220	A	20010129	NO 2000-6220	20001207
US 2003087306	A1	20030508	US 2001-15534	20011213
PRIORITY APPLN. INFO.:			US 1998-88466P	P 19980608
			US 1998-92938P	P 19980715
			WO 1999-US11786	W 19990604
			US 1999-327044	B1 19990607
			WO 1999-US11803	W 19990607
			WO 1999-US11804	W 19990607
			WO 1999-US11805	W 19990607
			WO 1999-US12669	W 19990607
			WO 1999-US12673	W 19990607
			WO 1999-US12727	W 19990607
			WO 1999-US12728	W 19990607
			WO 1999-US12730	W 19990607
			WO 1999-US12731	W 19990607
			WO 1999-US12778	W 19990607
			WO 1999-US12782	W 19990607
			US 1999-327904	B1 19990608
			WO 1999-US12626	W 19990608
			WO 1999-US12770	W 19990608
			WO 1999-US12876	W 19990608
			WO 1999-US12907	W 19990608
			WO 1999-US12989	W 19990608
			WO 1999-US12994	W 19990608
			WO 1999-US12995	W 19990608
			US 2000-493462	B1 20000128

OTHER SOURCE(S): MARPAT 134:131310

GI



AB Methods for preparing novel multibinding phenolic compds., LpXq [where L = a **ligand** capable of binding to a β 2-adrenergic **receptor**; X = a linker; p = 2-10; q = 1-20], which serve as β 2-adrenergic **receptor** agonists, are disclosed. Preferred ligands are of formula I [R1 = H, (un)substituted alkyl, or a bond linking **ligand** to linker; R2 = H, aralkyl, acyl, (un)substituted alkyl, cycloalkyl or a bond linking **ligand** to linker; W = bond, (un)substituted alkylene wherein one or more carbon atoms is optionally replaced by NR3, O, S, SO, SO2, CO, P-alkyl, PO2, OP(O)O or the alkylene optionally links the **ligand** to a linker with provisions; R3 = H, alkyl, acyl, or bond linking **ligand** to linker; X = aryl, heteroaryl, heterocyclyl and (un)substituted cycloalkyl wherein each X optionally links the **ligand** to the linker]. II was prepared from α,α -dihydroxy-4-hydroxy-3-methoxycarbonylacetophenone via condensation with trans-1,4-diaminocyclohexane with subsequent reduction of intermediate imine. In addition, combinatorial arrays of **multimeric** ligands and methods of assaying the **multimeric** ligands are embodied by the invention. As β 2-adrenergic **receptor** agonists, the compds. are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis (no data). The title compds. are also useful in the treatment of nervous system injuries and premature labor. Formulations for capsules, tablets, dry power inhaler, suppositories and suspensions are described.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:795681 CAPLUS

DOCUMENT NUMBER: 132:35606

TITLE: Preparation of multibinding piperidinylindole derivatives as therapeutic agents that modulate 5-HT receptors

INVENTOR(S): Marquess, Daniel; Griffin, John H.; Choi, Seok-Ki

PATENT ASSIGNEE(S): Advanced Medicine, Inc., USA

SOURCE: PCT Int. Appl., 190 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 31

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9964044	A1	19991216	WO 1999-US12751	19990607
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2318894	AA	19991216	CA 1999-2318894	19990604
AU 9945435	A1	19991230	AU 1999-45435	19990604
EP 1003540	A1	20000531	EP 1999-928344	19990604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002517457	T2	20020618	JP 2000-553099	19990604
CA 2318055	AA	19991216	CA 1999-2318055	19990607
CA 2318286	AA	19991216	CA 1999-2318286	19990607



CA 2319068	AA	19991216	CA 1999-2319068	19990607
CA 2319159	AA	19991216	CA 1999-2319159	19990607
CA 2319174	AA	19991216	CA 1999-2319174	19990607
CA 2319175	AA	19991216	CA 1999-2319175	19990607
CA 2319496	AA	19991216	CA 1999-2319496	19990607
CA 2319751	AA	19991216	CA 1999-2319751	19990607
CA 2319756	AA	19991216	CA 1999-2319756	19990607
CA 2321170	AA	19991216	CA 1999-2321170	19990607
CA 2321273	AA	19991216	CA 1999-2321273	19990607
AU 9944234	A1	19991230	AU 1999-44234	19990607
AU 9944253	A1	19991230	AU 1999-44253	19990607
AU 9944265	A1	19991230	AU 1999-44265	19990607
AU 9945491	A1	19991230	AU 1999-45491	19990607
AU 9945520	A1	19991230	AU 1999-45520	19990607
AU 9946727	A1	19991230	AU 1999-46727	19990607
AU 9946751	A1	19991230	AU 1999-46751	19990607
AU 9946752	A1	19991230	AU 1999-46752	19990607
AU 9946754	A1	19991230	AU 1999-46754	19990607
EP 1019360	A1	20000719	EP 1999-930123	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1080080	A1	20010307	EP 1999-930158	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1083917	A1	20010321	EP 1999-927291	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1083918	A1	20010321	EP 1999-927317	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1083893	A1	20010321	EP 1999-927331	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1083888	A1	20010321	EP 1999-928425	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1085887	A2	20010328	EP 1999-928349	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1085870	A2	20010328	EP 1999-930157	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1094826	A1	20010502	EP 1999-930156	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1100519	A1	20010523	EP 1999-930155	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1107753	A1	20010620	EP 1999-928457	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002517420	T2	20020618	JP 2000-553004	19990607
JP 2002517459	T2	20020618	JP 2000-553102	19990607
JP 2002517463	T2	20020618	JP 2000-553110	19990607
CA 2319497	AA	19991216	CA 1999-2319497	19990608
CA 2319643	AA	19991216	CA 1999-2319643	19990608
CA 2319651	AA	19991216	CA 1999-2319651	19990608
CA 2320926	AA	19991216	CA 1999-2320926	19990608
CA 2321120	AA	19991216	CA 1999-2321120	19990608
CA 2321152	AA	19991216	CA 1999-2321152	19990608
CA 2319650	AA	19991229	CA 1999-2319650	19990608
AU 9943368	A1	19991230	AU 1999-43368	19990608

AU 9943376	A1	19991230	AU 1999-43376	19990608
AU 9946747	A1	19991230	AU 1999-46747	19990608
AU 9952039	A1	19991230	AU 1999-52039	19990608
AU 9946776	A1	20000110	AU 1999-46776	19990608
EP 1082289	A1	20010314	EP 1999-930185	19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1083921	A1	20010321	EP 1999-955430	19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1085889	A2	20010328	EP 1999-928451	19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1085847	A2	20010328	EP 1999-928520	19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1085868	A1	20010328	EP 1999-930150	19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1085894	A1	20010328	EP 1999-937155	19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1102597	A1	20010530	EP 1999-955431	19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
SG 83723	A1	20011016	SG 1999-2842	19990608
JP 2002517442	T2	20020618	JP 2000-553068	19990608
US 6288055	B1	20010911	US 2000-499476	20000207
ZA 2000003475	A	20011011	ZA 2000-3475	20000711
ZA 2000004083	A	20011112	ZA 2000-4083	20000810
ZA 2000004085	A	20011112	ZA 2000-4085	20000810
ZA 2000004087	A	20011113	ZA 2000-4087	20000810
ZA 2000004084	A	20011119	ZA 2000-4084	20000810
ZA 2000004561	A	20011130	ZA 2000-4561	20000831
ZA 2000004565	A	20011130	ZA 2000-4565	20000831
US 2003087306	A1	20030508	US 2001-15534	20011213
PRIORITY APPLN. INFO.:				
			US 1998-88466P	P 19980608
			US 1998-92938P	P 19980715
			US 1998-96606P	P 19980814
			WO 1999-US11786	W 19990604
			US 1999-327044	B1 19990607
			WO 1999-US11803	W 19990607
			WO 1999-US11805	W 19990607
			WO 1999-US12669	W 19990607
			WO 1999-US12673	W 19990607
			WO 1999-US12727	W 19990607
			WO 1999-US12728	W 19990607
			WO 1999-US12730	W 19990607
			WO 1999-US12731	W 19990607
			WO 1999-US12751	W 19990607
			WO 1999-US12778	W 19990607
			WO 1999-US12782	W 19990607
			US 1999-327904	B1 19990608
			WO 1999-US12626	W 19990608
			WO 1999-US12770	W 19990608
			WO 1999-US12876	W 19990608
			WO 1999-US12907	W 19990608
			WO 1999-US12989	W 19990608
			WO 1999-US12994	W 19990608
			WO 1999-US12995	W 19990608
			US 2000-493462	B1 20000128

OTHER SOURCE(S):

MARPAT 132:35606

GI



AB Novel multibinding piperidinyndole compds, LpXq [where L = a **ligand** capable of binding to a 5-HT **receptor**; X = a linker; p = 2-10; q = 1-2], that modulate 5-HT receptors are disclosed. Preferred ligands are of formula I [where R3 and R5 = independently point of attachment of the linker, H, alkyl, heterocyclic, heteroaryl(alkyl), amidoalkyl, (di)alkylaminosulfonylalkyl, arylsulfonylalkyl, heterocyclosulfonylalkyl, arylcarbonylamino, alkylsulfonamido, or alkylsulfonylalkyl]. Over 140 multibinding compds., formed from two piperidinyndole derivs. and a difunctional linker, were prepared. For example, condensation of 5-(4-fluorobenzoyl)amino-3-(piperidin-4-yl)-1H-indole with 1,2-dibromoethane at 72° in DMF, after workup and chromatog., yielded the dimer II. Compds. of this invention are useful in the treatment of migraine, headache, itch, motion sickness, depression, emesis, memory loss, anxiolytic disorders, obesity, gastrointestinal disorders, and irritable bowel syndrome (no data). The multibinding compds. provide greater biol. and/or therapeutic effects than the aggregate of the unlinked ligands due to their multibinding properties (no data). Combinatorial arrays, methods of synthesis, and methods of assaying the **dimeric** and **multimeric** compds. are also embodied by the invention.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 20:38:41 ON 23 SEP 2004)

FILE 'REGISTRY' ENTERED AT 20:39:05 ON 23 SEP 2004

L1 STRUCTURE UPLOADED
L2 50 S SAM L1
L3 62637 S L1 FULL

FILE 'CAPLUS' ENTERED AT 20:48:04 ON 23 SEP 2004

L4 771 S L3 AND RECEPTOR
L5 73 S L4 AND LIGAND
L6 5 S L5 AND (DVALENT OR MULTIVALENT OR DIMERIC OR MULTIMERIC OR M

=> s l4 and G (3w) protein

2689246 G

1663885 PROTEIN

53947 G (3W) PROTEIN

L7 12 L4 AND G (3W) PROTEIN

=> d scan

L7 12 ANSWERS CAPLUS COPYRIGHT 2004 ACS on STN

IC ICM G01N033-58

ICS G01N033-68; G01N033-533

CC 9-11 (Biochemical Methods)

Section cross-reference(s): 1, 3, 13

TI Methods for detecting modulators of ion channels using thallium (i)
sensitive assays

ST thallium cell culture media ion channel **receptor** drug screening

IT Receptors

RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties);
ANST (Analytical study); BIOL (Biological study)
(5-hydroxytryptamine-gated; methods for detecting modulators of ion
channels using thallium (i) sensitive assays)

IT Glutamate receptors

RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties);
ANST (Analytical study); BIOL (Biological study)
(AMPA (α -amino-3-hydroxy-5-methyl-4-isoxazolepropionate);
methods for detecting modulators of ion channels using thallium (i)
sensitive assays)

IT Receptors

RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties);
ANST (Analytical study); BIOL (Biological study)
(ATP-gated; methods for detecting modulators of ion channels using
thallium (i) sensitive assays)

IT Potassium channel

RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties);
ANST (Analytical study); BIOL (Biological study)
(HERG; methods for detecting modulators of ion channels using thallium
(i) sensitive assays)

IT Potassium channel

RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties);
ANST (Analytical study); BIOL (Biological study)
(KCNQ; methods for detecting modulators of ion channels using thallium
(i) sensitive assays)

IT Potassium channel

RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties);
ANST (Analytical study); BIOL (Biological study)
(Maxi-K; methods for detecting modulators of ion channels using
thallium (i) sensitive assays)

IT Glutamate receptors

RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties);
ANST (Analytical study); BIOL (Biological study)
(NMDA-binding; methods for detecting modulators of ion channels using
thallium (i) sensitive assays)

IT Potassium channel

RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties);
ANST (Analytical study); BIOL (Biological study)
(SK(small conductance Ca²⁺ activated); methods for detecting modulators
of ion channels using thallium (i) sensitive assays)

IT Capsaicin receptors

RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties);
ANST (Analytical study); BIOL (Biological study)
(VR1; methods for detecting modulators of ion channels using thallium
(i) sensitive assays)

IT Cation channel

RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties);
 ANST (Analytical study); BIOL (Biological study)
 (cAMP, cGMP activated; methods for detecting modulators of ion channels
 using thallium (i) sensitive assays)

IT Ion channel
 RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties);
 ANST (Analytical study); BIOL (Biological study)
 (calcium-activated; methods for detecting modulators of ion channels
 using thallium (i) sensitive assays)

IT Transport proteins
 RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties);
 ANST (Analytical study); BIOL (Biological study)
 (calcium-sodium exchanger; methods for detecting modulators of ion
 channels using thallium (i) sensitive assays)

IT Receptors
 RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties);
 ANST (Analytical study); BIOL (Biological study)
 (channel-linked; methods for detecting modulators of ion channels using
 thallium (i) sensitive assays)

IT Buffers
 (chloride-free; methods for detecting modulators of ion channels using
 thallium (i) sensitive assays)

IT Gene
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (expression; methods for detecting modulators of ion channels using
 thallium (i) sensitive assays)

IT Transport properties
 (ionic; methods for detecting modulators of ion channels using thallium
 (i) sensitive assays)

IT Glutamate receptors
 RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties);
 ANST (Analytical study); BIOL (Biological study)
 (kainate; methods for detecting modulators of ion channels using
 thallium (i) sensitive assays)

IT Glutamate receptors
 RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties);
 ANST (Analytical study); BIOL (Biological study)
 (metabotropic; methods for detecting modulators of ion channels using
 thallium (i) sensitive assays)

IT Animal tissue culture
 Culture media
 Drug screening
 Fluorescence quenching
 Fluorescent substances
 Genetic methods
 Ionophores
 Mammalia
 (methods for detecting modulators of ion channels using thallium (i)
 sensitive assays)

IT 5-HT receptors
 Capsaicin receptors
 Cholinergic receptors
 Dopamine receptors
G protein-coupled receptors
 Inositol 1,4,5-trisphosphate receptors
 Ion channel
 Ryanodine receptors
 RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties);
 ANST (Analytical study); BIOL (Biological study)
 (methods for detecting modulators of ion channels using thallium (i)
 sensitive assays)

IT Amino acids, biological studies

Vitamins

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(methods for detecting modulators of ion channels using thallium (i) sensitive assays)

IT Receptors

RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study)

(nicotinic acetylcholine-gated; methods for detecting modulators of ion channels using thallium (i) sensitive assays)

IT Ion channel

RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study)

(voltage gated; methods for detecting modulators of ion channels using thallium (i) sensitive assays)

IT 5398-34-5, ANTS

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(ANTS; methods for detecting modulators of ion channels using thallium (i) sensitive assays)

IT 411209-52-4, Fluo 4FF pentapotassium salt

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(Fluo 4FF pentapotassium salt; methods for detecting modulators of ion channels using thallium (i) sensitive assays)

IT 411209-53-5, FluoZin 1

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(FluoZin 1; methods for detecting modulators of ion channels using thallium (i) sensitive assays)

IT 170516-42-4, Phen Green

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(Phen Green; methods for detecting modulators of ion channels using thallium (i) sensitive assays)

IT 7447-40-7, Potassium chloride, analysis

RL: ANT (Analyte); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ion co-transporters for; methods for detecting modulators of ion channels using thallium (i) sensitive assays)

IT 50-67-9, Serotonin, analysis 51-61-6, Dopamine, analysis 56-86-0, Glutamic acid, analysis

RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study)
(ion transporters for; methods for detecting modulators of ion channels using thallium (i) sensitive assays)

IT 24345-16-2, Apamin

RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(methods for detecting modulators of ion channels using thallium (i) sensitive assays)

IT 123632-39-3, Fluo-3 124549-11-7, PBFI 154324-80-8, BTC

170516-41-3, Magnesium Green 184228-02-2, Mag-Fura Red 216393-45-2, APTRA-BTC, tripotassium salt 273221-59-3, Fluo-4 411209-54-6, FluoZin 2 tetrapotassium salt

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(methods for detecting modulators of ion channels using thallium (i) sensitive assays)

IT 16887-00-6, Chloride, uses 20461-54-5, Iodide, uses 24959-67-9, Bromide, uses

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)
(methods for detecting modulators of ion channels using thallium (i) sensitive assays)

IT 50-99-7, D-Glucose, biological studies 51-84-3, Acetylcholine,

biological studies 54-11-5, Nicotine 56-85-9, Glutamine, biological studies 144-55-8, Sodium carbonate (NaHCO3), biological studies 299-27-4, Potassium gluconate 299-28-5, Calcium gluconate 300-54-9, Muscarine 462-58-8, Carbamylcholine 527-07-1, Sodium gluconate 3632-91-5, Magnesium gluconate 7365-45-9, HEPES 7440-28-0, Thallium, biological studies 7487-88-9, Sulfuric acid magnesium salt (1:1), biological studies 7558-80-7, Sodium phosphate (NaH2PO4) 14127-61-8, Calcium ion, biological studies 17341-25-2, Sodium ion, biological studies 22537-56-0, biological studies 24203-36-9, Potassium ion, biological studies

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(methods for detecting modulators of ion channels using thallium (i) sensitive assays)

IT 71-52-3, Hydrogen carbonate, biological studies 7791-12-0, Thallium chloride 10102-45-1, Thallium nitrate (TlNO3) 12026-06-1, Thallium hydroxide 14996-02-2, Hydrogen sulfate, biological studies 15843-14-8, Thallium acetate

RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)

(methods for detecting modulators of ion channels using thallium (i) sensitive assays)

IT 9000-83-3, ATPase

RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study)

(sodium-potassium and proton-potassium activated; methods for detecting modulators of ion channels using thallium (i) sensitive assays)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> d his

(FILE 'HOME' ENTERED AT 20:38:41 ON 23 SEP 2004)

FILE 'REGISTRY' ENTERED AT 20:39:05 ON 23 SEP 2004

L1 STRUCTURE UPLOADED

L2 50 S SAM L1

L3 62637 S L1 FULL

FILE 'CAPLUS' ENTERED AT 20:48:04 ON 23 SEP 2004

L4 771 S L3 AND RECEPTOR

L5 73 S L4 AND LIGAND

L6 5 S L5 AND (DIVALENT OR MULTIVALENT OR DIMERIC OR MULTIMERIC OR M

L7 12 S L4 AND G (3W) PROTEIN

=> d ibib abs 17 1-12

L7 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:2850 CAPLUS

DOCUMENT NUMBER: 140:77013

TITLE: Preparation of diphenylazetidinones for the treatment of hyperlipidemia, arteriosclerosis and hypercholesterolemia

INVENTOR(S): Jaehne, Gerhard; Frick, Wendelin; Flohr, Stefanie; Lindenschmidt, Andreas; Glombik, Heiner; Kramer, Werner; Heuer, Hubert; Schaefer, Hans-Ludwig

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany

SOURCE: PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000804	A1	20031231	WO 2003-EP5815	20030604
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10227506	A1	20040108	DE 2002-10227506	20020619
US 2004082561	A1	20040429	US 2003-463807	20030618
PRIORITY APPLN. INFO.:			DE 2002-10227506	A 20020619
			US 2002-411984P	P 20020919
OTHER SOURCE(S):	MARPAT 140:77013			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1, R2, R3, R4, R5, R6 = (un)substituted alkylene-(LAG)n; n = 1-5; LAG = sugar; amino sugar; amino acid, etc.] and their pharmaceutically acceptable salts were prepared For example, N-alkylation of 1,4-diazabicyclo[2.2.2]octane with benzyl bromide II, e.g., prepared from 1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone and 1,2-bisbromomethylbenzene, afforded diphenylazetidinone III. In rat liver chloesterol absorption assays, 26-examples of compds. I exhibited EC50 values ranging from 0.03-<1.0 (mg/mouse), e.g., the EC50 value of diphenylazetidinone III was 0.3. Compds. I are claimed useful for the treatment of hyperlipidemia, arteriosclerosis and hypercholesterolemia.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:491222 CAPLUS

DOCUMENT NUMBER: 139:69258

TITLE: Preparation of pyrazolopyridine derivatives as Edg-5 **receptor** antagonists

INVENTOR(S): Ozawa, Koichi; Hirata, Kazuyuki; Yamamoto, Kazuhiko

PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan

SOURCE: PCT Int. Appl., 198 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051876	A1	20030626	WO 2002-JP13059	20021213
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,			

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
 PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
 UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

JP 2001-382398

A 20011214


JP 2002-225343

A 20020801


OTHER SOURCE(S):

MARPAT 139:69258

GI



I



II

AB The title pyrazolopyridine derivs. with general formula of I [wherein R1 = H, (halo)alkyl, (un)substituted aryl, aralkyl, or COR7; R7 = alkyl, alkoxy, (un)substituted aryl, aralkyl, aryloxy, or aralkyloxy; R2 = H, (un)substituted alkyl, or aryl; R3 = H, alkoxy, alkoxy-CO, haloalkyl, cycloalkyl, (un)substituted alkyl, or aryl; R4 = H or (un)substituted alkyl; R5 = H, (cyclo)alkyl, alkoxy, alkoxy-CO, carboxy, alkynyl, halo, CN, NO2, haloalkyl, alkylamino, dialkylamino, acyl, OH, (un)substituted aryloxy, aralkyloxy, aryl, aralkyl, heterocyclyl, alkoxyalkyl, or CONHR8; R8 = (un)substituted aryl or aralkyl; R6 = H, (cyclo)alkyl, alkoxy, alkoxy-CO, carboxy, alkynyl, halo(alkyl), CN, NO2, alkylamino, dialkylamino, acyl, OH, (un)substituted aryloxy, aralkyloxy, aryl, aralkyl, heterocyclyl, alkoxyalkyl, or CONHR8; X = O, -N=, -CH=, (un)substituted -NH-, or -CH2-; Y = =N-, -CH2-, =CH-, -O-, -CO-, a bond, or (un)substituted -NH-; Z = CO, CS, CH2, O, or a bond; W = O, CO, CONH, CH2, NHCH2, a bond, or (un)substituted -NH-; ring A = aryl, heterocyclyl, or cycloalkyl] and prodrugs and pharmaceutically acceptable salts thereof are prepared. For example, the compound II was prepared in a multi-step synthesis. II showed IC50 of 0.014 μ M against hAGR16 in cow. I act specifically on endothelial differentiation sphingolipid G-protein-coupled (Edg) 5 which is a sphingosine-1-phosphate receptor and, therefore, are useful as remedies for fibrosis, arteriosclerosis, coronary vasospasm, asthma, nephritis, nerve disorder, peripheral nerve disorder, rheumatoid arthritis, systemic lupus erythematosus (SLE), cancer, etc.

REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



ACCESSION NUMBER: 2003:42372 CAPLUS
 DOCUMENT NUMBER: 138:102021
 TITLE: cDNAs encoding human olfactory cyclic nucleotide gated (CNG) channel subunits for use in enhancing smell receptors
 INVENTOR(S): Zoller, Mark T.; Xu, Hong; Staszewski, Lena; Moyer, Bryan; Pronin, Alexy; Adler, Jon Elliott; Servant, Guy; Callamaras, Nicholas
 PATENT ASSIGNEE(S): Senomyx, Inc., USA
 SOURCE: PCT Int. Appl., 97 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003004611	A2	20030116	WO 2002-US21184	20020708
WO 2003004611	A3	20040226		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003228633	A1	20031211	US 2002-189507	20020708
EP 1414940	A2	20040506	EP 2002-765797	20020708
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRIORITY APPLN. INFO.:			US 2001-303140P	P 20010706
			US 2001-337154P	P 20011210
			WO 2002-US21184	W 20020708
AB The present invention relates to isolated nucleic acid sequences that encode human olfactory cyclic nucleotide gated (CNG) channel subunits, and the corresponding polypeptides. The invention further relates to the use of human CNG channels to profile, screen for, and identify compds. that modulate the human olfactory CNG channel. More specifically, the invention relates to the expression of the human olfactory CNG channel in cells, preferably mammalian cells, and the use of these cells in high throughput cell-based assays to identify compds. that enhance or block human olfactory CNG function. Compds. that activate the olfactory CNG channel will enhance smell and can be used to make foods more palatable for individuals with attenuated olfactory function. Conversely, compds. that inhibit the olfactory CNG channel will inhibit smell and can be used to block malodors. Addnl., the invention relates to the use of cell-based olfactory CNG channel assays to identify modulators of G-protein coupled receptor (GPCRs) and other proteins that regulate cyclic nucleotide levels. Claimed sequence ID#4 is missing.				

L7 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:5937 CAPLUS
 DOCUMENT NUMBER: 138:73273
 TITLE: Preparation of [1,2']bipyrazinyl 5-HT2 **receptor** ligands for treatment of sexual dysfunction
 INVENTOR(S): Chiang, Yuan-Ching Phoebe; Dasilva-Jardine, Paul

Andrew; Garigipati, Ravi S.; Guzman-Perez, Angel;
 Novomisle, William Albert; Welch, Willard Mckowan
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 151 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000666	A1	20030103	WO 2002-IB2293	20020617
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003105106	A1	20030605	US 2002-156884	20020528
US 2003125334	A1	20030703	US 2002-163881	20020605
NZ 529542	A	20031219	NZ 2002-529542	20020617
NZ 529543	A	20031219	NZ 2002-529543	20020617
EP 1401820	A1	20040331	EP 2002-735869	20020617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200400026	A	20040615	EE 2004-26	20020617
BR 2002010471	A	20040810	BR 2002-10471	20020617
PRIORITY APPLN. INFO.:			US 2001-299953P	P 20010621
			WO 2002-IB2293	W 20020617
OTHER SOURCE(S):			MARPAT 138:73273	
GI				



AB Title compds. (I) [wherein X and Z = independently CR; R = H, halo,
 alkyl(amino), or amino; W = O, S, NH, alkylamino, or acetylamino; at least
 one of R1, R5, R6, or R7 = independently halo, NO2, (alkyl)amino, CN,
 CONH2, (halo)alkyl, or alkoxy; or C2R1R5 = 5- or 6-membered aromatic or fused
 ring; or R1 taken together with R2 or R8 forms a 5- or 6-membered fused

ring; R2 and R8 = independently H or (cyclo)alkyl; n = 0-2; R3 and R9 = independently H, halo, alkyl, or alkyl substituted with OH, F, or alkoxy; R4 = H, OH, (hydroxy)alkyl, cyanoalkyl, alkylcarbonyl, alkoxy(carbonyl), or alkenyl; or N-oxides, prodrugs, pharmaceutically acceptable salts, solvates, or hydrates thereof] were prepared as 5-hydroxytryptamine (5-HT) **receptor** ligands, in particular 5-HT2C **receptor** ligands.

For instance, 2,6-dichloropyrazine was coupled with piperazine-1-carboxylic acid tert-Bu ester using Na2CO3 in t-BuOH to give 6'-chloro-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-carboxylic acid tert-Bu ester. Substitution with 3-chlorobenzyl alc. in the presence of KOH and 18-crown-6 in toluene followed by deesterification afforded 6'-(3-chlorobenzoyloxy)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl (II). Compds. of the invention demonstrated affinity at the serotonin 5HT2A and 5HT2C binding sites with Ki values ranging from 0.5 nM to 1.0 µM and 0.1 nM to 586.5 nM, resp. In a functional assay using 5-HT2C expressed NIH 3T3 cells, II displayed EC50 ≤ 1.0 µM. I and pharmaceutical compns. containing I are useful for the treatment of diseases linked to the activation of 5-HT2 receptors, such as sexual dysfunction (no data).

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:521710 CAPLUS

DOCUMENT NUMBER: 137:93690

TITLE: Preparation of nicotinanilide-N-oxides as G-
protein-coupled receptor antagonist
for the treatment of inflammation due to neutrophil
chemotaxis

INVENTOR(S): Cutshall, Neil S.; Yager, Kraig M.

PATENT ASSIGNEE(S): Darwin Discovery Ltd., UK

SOURCE: PCT Int. Appl., 73 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053544	A1	20020711	WO 2001-US47543	20011212
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003004189	A1	20030102	US 2001-15861	20011212
PRIORITY APPLN. INFO.:			US 2000-258730P	P 20001229
OTHER SOURCE(S):	MARPAT 137:93690			
GI				



AB Title compds. I, their optical isomers, diastereomers, enantiomers and pharmaceutically acceptable salts [wherein: R1 = R5, R5-heteroalkylene; R5 = H, halo, alkyl, heteroalkyl, etc.; R2, R3 = H, alkyl, heteroalkyl, aryl, etc.; R4 = H, halo, alkyl, heteroalkyl, etc.] were claimed. For example, hydrogen peroxide mediated N-oxidation of 2-chloro-N-(4-fluorophenyl)-6-methylnicotinamide provided claimed oxynicotinamide II in 10% yield. Nicotinanilide N-oxides I are disclosed to inhibit chemokine-mediated cellular and inflammation events. Specific binding of 95 claimed examples to human interleukin 8 and human growth-regulatory oncogene- α (GRO- α) chemokine were reported as < or > 40% at 20 μ M ligand concentration, e.g., compound II > 40% for GRO- α , were disclosed. Also, the specific binding of 9 claimed examples to human chemokine CCR5, human interleukin-CXCR1, human interleukin-CXCR2, human neuropeptide Y1 and somatostatin, e.g., compound II: < 40% for CCR5, somatostatin; > 40% for CXCR1, CXCR2; no data for NYP1, were disclosed. A method for the identification of nicotinanilide-N-oxides. I receptors from cell or cellular components and the isolation of compds. I which bind to TNF- α signaling proteins via affinity bead chromatog. and surface plasmon resonance (SPR) are claimed (no data).

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:293976 CAPLUS

DOCUMENT NUMBER: 136:321701

TITLE: Methods for detecting modulators of ion channels using thallium (i) sensitive assays

INVENTOR(S): Weaver, Charles David

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002031508	A1	20020418	WO 2001-US32132	20011012
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002015350	A5	20020422	AU 2002-15350	20011012

US 2002168625 A1 20021114 US 2001-975891 20011012
EP 1327150 A1 20030716 EP 2001-983962 20011012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: US 2000-240523P P 20001013
WO 2001-US32132 W 20011012

AB The invention concerns novel thallium-sensitive assays for identifying modulators of ion channels, channel-linked receptors or ion transporters are provided. The invention further provides novel chloride-free buffers and low chloride cell growth media.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:230597 CAPLUS

DOCUMENT NUMBER: 138:1793

TITLE: Development of Gs-selective inhibitory compounds

AUTHOR(S): Nanoff, Christian; Kudlacek, Oliver; Freissmuth, Michael

CORPORATE SOURCE: Institute of Pharmacology, University of Vienna, Vienna, A-1090, Austria

SOURCE: Methods in Enzymology (2002), 344(G Protein Pathways, Part B), 469-480

CODEN: MENZAU; ISSN: 0076-6879

PUBLISHER: Academic Press

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review on the three types of effects exerted by the active compds., **G protein** α subunits, to determine their usefulness in expts. in intact cells and animals. These effects are the inhibition of GDP release, the inhibition of **receptor-G protein** coupling, and the inhibition of effector regulation. The availability of biochem. assays should help in overcoming the limitation posed by the fact that the compds. are not membrane permeable. The structure of a complex was also solved in which G α s is bound to a dimer formed by the catalytic domains of adenylyl cyclase. Thus, a structural model is available that may guide the search for improved inhibitors of G α s. (c) 2002 Academic Press.

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:884055 CAPLUS

DOCUMENT NUMBER: 136:227068

TITLE: Pharmacological analysis of CCK2 **receptor** ligands using COS-7 and SK-N-MC cells, expressing the human CCK2 **receptor**

AUTHOR(S): Nilsson, Isabelle; Monstein, Hans-Jurg; Lindstrom, Erik; Hakanson, Rolf; Svensson, Samuel

CORPORATE SOURCE: Division of Pharmacology, Faculty of Health Sciences, University of Linkoping, University Hospital, Linkoping, S-581 85, Swed.

SOURCE: Regulatory Peptides (2002), 103(1), 29-37

CODEN: REPPDY; ISSN: 0167-0115

PUBLISHER: Elsevier Science Ireland Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of CCK2 **receptor** ligands were analyzed with respect to their interaction with binding sites in the membranes of COS-7 cells and SK-N-MC cells transiently expressing the human CCK2 **receptor** (short isoform). The ligands were YF476, YM022, AG041R, L-740,093, JB93182, PD134308, and PD136450. Their binding was analyzed by

radioligand competition using [3H]L-365,260 as the labeled ligand. Saturation binding anal. indicated that [3H]L-365,260 interacted with a single class of binding sites. In competition binding expts. using COS-7-cell membranes, all seven ligands were incubated together with 2 nM [3H]L-365,260. The data for four of the compds. fitted a one-site model (pKi values: YM022: 9.2; YF476: 9.6; L-740,093: 9.2; and AG041R: 8.3), while the data for the three others fitted a two-site model (pKi values: JB93182: 8.8 and 6.0; PD134308: 9.0 and 6.1; and PD136450: 9.0 and 5.4). SK-N-MC cell membranes and 2 nM [3H]L-365,260 were incubated together with YM022, YF476, JB93182, and PD134308. The data for YM022 and YF476 fitted a one-site model (pKi values: YM022: 9.3; YF476: 9.4), while the data for JB93182 and PD134308 fitted a two-site model (pKi values: JB93182: 8.7 and 6.2; PD134308: 9.1 and 7.0). Competition binding expts. in the presence of the GTP-analog guanylylimidodiphosphate, using either of the two cell types, produced similar binding data for PD134308 and JB93182 as in the absence of GTP-analog. The human **receptor** seems to exist in a low and/or high affinity state. The shift from low to high affinity does not seem to reflect the degree of **G protein** coupling.

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:96227 CAPLUS

DOCUMENT NUMBER: 130:153665

TITLE: Preparation of arylpyrimidinediones as P2-purinoceptor 7-transmembrane **G-protein** coupled **receptor** antagonists.

INVENTOR(S): Kindon, Nicholas; Meghani, Premji; Thom, Stephen

PATENT ASSIGNEE(S): Astra Pharmaceuticals Ltd., UK; Astra Aktiebolag

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9905123	A1	19990204	WO 1998-SE1391	19980715
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9883704	A1	19990216	AU 1998-83704	19980715
EP 1000038	A1	20000517	EP 1998-934105	19980715
EP 1000038	B1	20021106		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001510833	T2	20010807	JP 2000-504122	19980715
AT 227276	E	20021115	AT 1998-934105	19980715
US 6200981	B1	20010313	US 1999-155091	19990921
PRIORITY APPLN. INFO.:			SE 1997-2794	A 19970724
			WO 1998-SE1391	W 19980715
OTHER SOURCE(S):		MARPAT 130:153665		
GI				



AB Title compds. [I; X = bond, CH₂, (O-interrupted) C1-3 alkylene; R = H, NO₂, NH₂, dialkylamino, CO₂H, CH₂OH, halo, alkoxy carbonyl, (substituted) (O-, S-, or N-interrupted) alkyl, etc.; R₁ = amino, aminomethyl, carboxymethylaminomethyl, (O-, S-, or N-interrupted) (substituted) alkyl, etc.; R₂ = (substituted) fluorenyl, dibenzocycloheptenyl, etc.; Q₁, Q₂ = O, S], were prepared as P2-purinoceptor 7-transmembrane **G-protein** coupled **receptor** antagonists. Thus, 2',3',5'-tris-O-[(1,1-dimethylethyl)dimethylsilyl]uridine and Me₂NCH₂CH₂NMe₂ in THF at -78° were treated with *s*-BuLi and then with 9-fluorenone in THF followed by stirring overnight at room temperature to give 5-(9-hydroxy-9H-fluoren-9-yl)-2',3',5'-tris-O-[(1,1-dimethylethyl)dimethylsilyl]uridine. The latter was treated with Et₃SiH and BF₃·Et₂O in CH₂Cl₂ to give a residue which was treated with Bu₄NF in THF to give 5-(9H-fluoren-9-yl)uridine. This was refluxed with aqueous HCl in EtOH to give 5-(9H-fluoren-9-yl)-3,4-dihydro-2,4(1H,3H)-pyrimidinedione. Stirring of the latter with Et₄NOH and Me 3-bromomethylbenzoate in DMF gave Me 3-[[5-(9H-fluoren-9-yl)-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzoate. This was refluxed with Lawesson's reagent in THF followed by saponification of the product with LiOH in THF/H₂O to give 3-[[5-(9H-fluoren-9-yl)-3,4-dihydro-2-oxo-4-thioxo-1(2H)-pyrimidinyl]methyl]benzoic acid. I bound to P2-purinoceptor 7-transmembrane **G-protein** coupled receptors with pA₂ >4.0.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:33926 CAPLUS

DOCUMENT NUMBER: 128:188589

TITLE: Gα-selective **G protein** antagonists

AUTHOR(S): Hohenegger, M.; Waldhoer, M.; Beindl, W.; Boing, B.; Kreimeyer, A.; Nickel, P.; Nanoff, C.; Freissmuth, M.

CORPORATE SOURCE: Institute of Pharmacology, University of Vienna, A-1090, Austria

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1998), 95(1), 346-351
CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Suramin acts as a **G protein** inhibitor because it inhibits the rate-limiting step in activation of the Gα subunit, i.e., the exchange of GDP for GTP. Here, we have searched for analogs that are selective for Gα. Two compds. have been identified: NF449 (4,4',4'',4'''-[carbonyl-bis[imino-5,1,3-benzenetriyl bis-(carbonylimino)]] tetrakis-(benzene-1,3-disulfonate) and NF503 (4,4'-[carbonylbis[imino-3,1-phenylene-(2,5-benzimidazolylene)carbonylimino]]bis-benzenesulfonate). These compds. (i) suppress the association rate of guanosine

5'-[γ-thio]triphosphate ([35S]GTP[γS]) binding to Gsα-s but not to Giα-1, (ii) inhibit stimulation of adenylyl cyclase activity in S49 cyc- membranes (deficient in endogenous Gsα) by exogenously added (Gsα-s, and (iii) block the coupling of β-adrenergic receptors to Gs with half-maximum effects in the low micromolar range. In contrast to suramin, which is not selective, NF503 and NF449 disrupt the interaction of the A1-adenosine **receptor** with its cognate G proteins (Gi/Go) at concns. that are >30-fold higher than those required for uncoupling of β-adrenergic **receptor** /Gs tandems; similarly, the angiotensin II type-1 **receptor** (a prototypical Gq-coupled **receptor**) is barely affected by the compds. Thus, NF503 and NF449 fulfill essential criteria for Gsα-selective antagonists. The observations demonstrate the feasibility of subtype-selective **G protein** inhibition.




REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1993:603874 CAPLUS
DOCUMENT NUMBER: 119:203874
TITLE: Preparation of aromatic peptidomimetics
INVENTOR(S): Hirschmann, Ralph; Leahy, Ellen; Sprengeler, Paul
PATENT ASSIGNEE(S): University of Pennsylvania, USA
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9312084	A1	19930624	WO 1992-US10694	19921211
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5250564	A	19931005	US 1991-806048	19911212
PRIORITY APPLN. INFO.:			US 1991-806048	19911212
OTHER SOURCE(S):	MARPAT	119:203874		

GI



AB Title compds. I [R1 = RA(CH₂)_nOCH₂, RA'(CH₂)_nO₂CCH₂, RA(CH₂)_n, RA(CH₂)_nCOCH₂ wherein RA = H, C1-14 alkyl, C1-14 alkenyl and ≤4 N, n = 0-12; R2, R3, R4 = RB(CH₂)_mOCH₂, RB(CH₂)_mO₂CCH₂, RB(CH₂)_m, RB(CH₂)_mCOCH₂, wherein RB = H, C'6-14 aryl, m = 0-5; R5 = RC'NH(CH₂)_p RD(CH₂)_p, etc. wherein RC = H, C1-14 alkyl, C1-14 alkenyl, etc.; RD = H, HO, HCO, etc., p = 0-10; R6 = H, HO] or a salt thereof, useful for modulating the activity of at least one mammalian **G-protein-linked receptor**, are prepared
1,2,4,5-Tetraformylbenzene in 10N KOH was stirred at room temperature for 5 h to give II which in 7 steps was converted to title compound III. The affinity of I for substance P **receptor** was shown.

L7 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1989:592173 CAPLUS
DOCUMENT NUMBER: 111:192173
TITLE: Magnesium and cell proliferation
AUTHOR(S): Maguire, Michael E.
CORPORATE SOURCE: Sch. Med., Case Western Reserve Univ., Cleveland, OH, 44106, USA
SOURCE: Annals of the New York Academy of Sciences (1988), 551(Membr. Cancer Cells), 201-17
CODEN: ANYAA9; ISSN: 0077-8923
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Preliminary data using cell-permeable Mg²⁺ indicators based on tropolone suggest the feasibility of the dynamic and selective determination of intracellular free Mg²⁺ concentration in mammalian cells. Mg²⁺-deficient cell lines were also developed. Murine S49 lymphoma cells in normal 0.8 mM Mg²⁺ medium double in 17 h, but die when placed in 0.2 mM Mg²⁺ medium. Two classes of S49 clones were isolated which grow in 30 μM Mg²⁺ with doubling times of 22 and 60 h. Although total cell Mg²⁺ is decreased by 50%, the decrease is selective, since cytoplasmic Mg²⁺ is decreased 75%, whereas particulate Mg²⁺ is unchanged. Hormonal response in the Mg²⁺-deficient cells is defective. CAMP accumulation in response to β-adrenergic **receptor** activation is decreased >95%. In contrast, the Mg²⁺-deficient cells lose only .apprx.50% of their response to PGE₁ **receptor** activation, retain 50% of their β-receptors, and accumulate CAMP in response to cholera toxin at the wild-type rate. Mg²⁺ transport also occurs at the wild-type rate, but with a slightly higher affinity, and is not longer hormone-sensitive. Ca²⁺ content is normal or slightly high. T-lymphocytes isolated from rats made Mg²⁺-deficient for 8 wk give similar results, indicating that the Mg²⁺-deficient S49 lymphoma cell clones are a good model for Mg²⁺-deficiency. Apparently, lack of Mg²⁺ causes growth abnormalities and leads to markedly altered **receptor-G protein** coupling, but may have less effect on **G-protein** -adenylate cyclase interaction.

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	88.28	246.01
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-11.90	-11.90

FILE 'STNGUIDE' ENTERED AT 21:01:25 ON 23 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Sep 17, 2004 (20040917/UP).

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.06

246.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-11.90

FILE 'CAPLUS' ENTERED AT 21:02:16 ON 23 SEP 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Sep 2004 VOL 141 ISS 13

FILE LAST UPDATED: 22 Sep 2004 (20040922/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 20:38:41 ON 23 SEP 2004)

FILE 'REGISTRY' ENTERED AT 20:39:05 ON 23 SEP 2004

L1 STRUCTURE UPLOADED

L2 50 S SAM L1

L3 62637 S L1 FULL

FILE 'CAPLUS' ENTERED AT 20:48:04 ON 23 SEP 2004

L4 771 S L3 AND RECEPTOR

L5 73 S L4 AND LIGAND

L6 5 S L5 AND (DVALENT OR MULTIVALENT OR DIMERIC OR MULTIMERIC OR M

L7 12 S L4 AND G (3W) PROTEIN

FILE 'STNGUIDE' ENTERED AT 21:01:25 ON 23 SEP 2004

FILE 'CAPLUS' ENTERED AT 21:02:16 ON 23 SEP 2004

=> s l4 and muscarinic

23368 MUSCARINIC

L8 10 L4 AND MUSCARINIC

=> d scan l8

L8 10 ANSWERS CAPLUS COPYRIGHT 2004 ACS on STN

IC ICM C07C229-60

ICS A61K031-136; A61K031-33; A61P043-00; C07C217-84; C07C217-86;
C07C217-70; C07C233-43; C07D239-42; C07D239-46; C07D413-12;
C07D409-12; C07D401-12; C07C311-44

CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1

TI Preparation of aryl aniline β -2 adrenergic **receptor**
agonists

ST aryl pyrimidines aniline adrenergic **receptor** agonist prepn

IT Cytokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antagonist; combination pharmaceutical; preparation of aryl aniline
 β -2 adrenergic **receptor** agonists for treatment of
pulmonary disorders)

IT Lung, disease
(chronic obstructive; preparation of aryl aniline β -2 adrenergic
receptor agonists for treatment of pulmonary disorders)

IT Leukotriene antagonists
Muscarinic antagonists
(combination pharmaceutical; preparation of aryl aniline β -2 adrenergic
receptor agonists for treatment of pulmonary disorders)

IT Antibodies and Immunoglobulins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; preparation of aryl aniline β -2 adrenergic
receptor agonists for treatment of pulmonary disorders)

IT Parturition
(premature; preparation of aryl aniline β -2 adrenergic **receptor**
agonists for treatment of pulmonary disorders)

IT Anti-inflammatory agents
Heart, disease
Human
Inflammation
Lung, disease
Nervous system, disease
(preparation of aryl aniline β -2 adrenergic **receptor** agonists
for treatment of pulmonary disorders)

IT Adrenoceptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β 1; preparation of aryl aniline β -2 adrenergic **receptor**
agonists for treatment of pulmonary disorders)

IT Adrenoceptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β 2; preparation of aryl aniline β -2 adrenergic **receptor**
agonists for treatment of pulmonary disorders)

IT 15826-37-6, Sodium cromoglycate 37205-61-1, Protease inhibitor
69049-74-7, Nedocromil sodium
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; preparation of aryl aniline β -2 adrenergic
receptor agonists for treatment of pulmonary disorders)

IT 9025-82-5, Phosphodiesterase
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitor; combination pharmaceutical; preparation of aryl aniline β -2
adrenergic **receptor** agonists for treatment of pulmonary
disorders)

IT **530117-15-8P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of aryl aniline β -2 adrenergic **receptor** agonists
for treatment of pulmonary disorders)

IT **530084-30-1P 530084-38-9P 530084-55-0P**

530084-56-1P 530084-57-2P 530084-58-3P
 530084-59-4P 530084-60-7P 530084-61-8P 530084-62-9P
 530084-63-0P 530084-64-1P 530084-65-2P 530084-66-3P 530084-87-8P
 530084-88-9P 530116-67-7P 530116-69-9P
 530116-71-3P 530116-73-5P 530116-75-7P
 530116-77-9P 530116-79-1P 530116-81-5P
 530116-83-7P 530116-85-9P 530116-87-1P 530116-89-3P
 530116-91-7P 530116-93-9P 530116-95-1P
 530116-97-3P 530116-99-5P 530117-01-2P
 530117-03-4P 530117-05-6P 530117-07-8P
 530117-09-0P 530117-11-4P 530117-13-6P
 530117-16-9P 530117-18-1P 530117-20-5P
 530117-22-7P 530117-24-9P 530117-26-1P
 530117-28-3P 530117-29-4P 530117-30-7P
 530117-31-8P 530117-32-9P 530117-33-0P 530117-35-2P
 530117-37-4P 530117-39-6P 530117-41-0P 530117-43-2P
 530117-46-5P 530117-48-7P 530117-49-8P 530117-50-1P 530117-51-2P
 530117-52-3P 530117-53-4P 530117-54-5P 530117-56-7P 530117-58-9P
 530117-60-3P 530117-62-5P 530117-64-7P 530117-66-9P 530117-67-0P
 530117-68-1P 530117-70-5P 530117-71-6P 530117-72-7P 530117-74-9P
 530117-76-1P 530117-78-3P 530117-80-7P 530117-82-9P 530117-84-1P
 530117-86-3P 530117-88-5P 530117-90-9P 530117-92-1P 530117-93-2P
 530117-94-3P 530117-96-5P 530117-98-7P 530118-00-4P 530118-01-5P
 530118-02-6P 530118-04-8P 530118-06-0P 530118-07-1P 530118-08-2P
 530118-09-3P 530118-10-6P 530118-11-7P 530118-12-8P 530118-13-9P
 530118-14-0P 530118-15-1P 530118-17-3P 530118-19-5P 530118-20-8P
 530118-21-9P 530118-22-0P 530118-23-1P 530118-24-2P 530118-25-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of aryl aniline β -2 adrenergic **receptor** agonists
 for treatment of pulmonary disorders)

IT 57-68-1 77-76-9, 2,2-Dimethoxypropane 79-72-1 92-67-1,
 4-Aminobiphenyl 98-80-6, Phenylboronic acid 100-52-7, Benzaldehyde,
 reactions 104-96-1, 4-(Methylthio)aniline 144-83-2 312-35-6,
 4-[(4-Fluorophenyl)sulfonyl]aniline 461-82-5, 4-
 (Trifluoromethoxy)aniline 587-02-0, 3-Ethylaniline 619-45-4, Methyl
 4-aminobenzoate 651-06-9 1127-45-3, 8-Hydroxyquinoline-N-oxide
 1679-18-1, 4-Chlorophenylboronic acid 1783-81-9, 3-(Methylthio)aniline
 2316-64-5, 5-Bromo-2-hydroxybenzyl alcohol 4534-11-6,
 3-Methyl-4-isopropylaniline hydrochloride 5197-28-4,
 2-Bromo-4-nitroanisole 5470-49-5, 4-(Methylsulfonyl)aniline 6315-89-5,
 3,4-Dimethoxyaniline 6336-68-1 6973-47-3 7019-01-4,
 4-(Phenylsulfonyl)aniline 7146-68-1, 4-(4-Chlorobenzenesulfonyl)phenylam
 ine 7525-23-7 13472-00-9, 4-Aminophenethylamine 21626-70-0
 24313-88-0, 3,4,5-Trimethoxyaniline 26815-49-6, 3-Aminodiphenyl sulfone
 51123-09-2 51388-20-6, 4-Benzyloxyaniline hydrochloride 51628-12-7,
 4-Iodophenylacetonitrile 63503-60-6, 3-Chlorophenylboronic acid
 73918-56-6, 4-Bromophenethylamine 75705-21-4, 4-
 (Aminomethyl)phenylboronic acid hydrochloride 76590-35-7,
 4-(o-Tolylthio)aniline 78191-00-1, N-Methyl-N-methoxyacetamide
 83527-99-5 92028-21-2, 4-Methoxy-3-phenylaniline hydrochloride
 92903-03-2, 4-Amino-2-cyclohexylphenol 114306-97-7 135884-31-0
 146631-00-7, 4-Benzyloxyphenylboronic acid 150255-96-2,
 3-Cyanophenylboronic acid 175136-34-2 397242-08-9,
 4-[(4-Methylpyrimidin-2-yl)thio]benzeneamine 530118-81-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of aryl aniline β -2 adrenergic **receptor** agonists
 for treatment of pulmonary disorders)

IT 15450-72-3P, 8-Acetoxy-2(1H)-quinolinone 19434-42-5P 52113-69-6P
 54030-34-1P 62978-73-8P, 5-Acetyl-8-hydroxy-2(1H)-quinolinone
 73918-57-7P, 4-Iodophenethylamine 93609-84-8P, 5-Acetyl-8-benzyloxy-

2(1H)-quinolinone 100331-89-3P 102293-80-1P 530084-67-4P
 530084-68-5P 530084-69-6P 530084-71-0P **530084-72-1P**
 530084-74-3P 530084-75-4P 530084-76-5P 530084-77-6P 530084-78-7P
 530084-80-1P 530084-81-2P 530084-82-3P 530084-84-5P 530118-35-5P
 530118-37-7P 530118-41-3P **530118-42-4P 530118-47-9P**
 530118-49-1P 530118-52-6P 530118-61-7P 530118-63-9P 530118-65-1P
 530118-66-2P 530118-68-4P 530118-70-8P, 2-(3-Cyanophenyl)-4-
 nitroanisole 530118-72-0P, 3-(3-Cyanophenyl)-4-methoxyaniline
 530118-75-3P, 2-(4-Aminomethylphenyl)-4-nitroanisole 530118-76-4P,
 2-(3-Chlorophenyl)-4-nitroanisole 530118-78-6P, 3-(3-Chlorophenyl)-4-
 methoxyaniline 530118-80-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of aryl aniline β -2 adrenergic **receptor** agonists
 for treatment of pulmonary disorders)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> d his

(FILE 'HOME' ENTERED AT 20:38:41 ON 23 SEP 2004)

FILE 'REGISTRY' ENTERED AT 20:39:05 ON 23 SEP 2004

L1 STRUCTURE UPLOADED

L2 50 S SAM L1

L3 62637 S L1 FULL

FILE 'CAPLUS' ENTERED AT 20:48:04 ON 23 SEP 2004

L4 771 S L3 AND RECEPTOR

L5 73 S L4 AND LIGAND

L6 5 S L5 AND (DIVALENT OR MULTIVALENT OR DIMERIC OR MULTIMERIC OR M

L7 12 S L4 AND G (3W) PROTEIN

FILE 'STNGUIDE' ENTERED AT 21:01:25 ON 23 SEP 2004

FILE 'CAPLUS' ENTERED AT 21:02:16 ON 23 SEP 2004

L8 10 S L4 AND MUSCARINIC

=> d ibib abs 18 1-10

L8 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:703125 CAPLUS

TITLE: Preparation of biphenyl derivatives as
 β 2-adrenergic agonists and **muscarinic**
 antagonists for pulmonary disorders.

INVENTOR(S): Mammen, Mathai; Dunham, Sarah; Hughes, Adam; Lee, Tae
 Weon; Husfeld, Cralg; Stangeland, Eric

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 85 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004167167	A1	20040826	US 2004-779157	20040213
WO 2004074276	A1	20040902	WO 2004-US4224	20040213
W:	AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG,			
	BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR,			
	CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES,			

ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN,
 IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC,
 LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX,
 MZ, MZ, NA, NI
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
 BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
 MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, ML, MR, NE, SN, TD, TG



WO 2004074812 A2 20040902 WO 2004-US4273 20040213
 W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG,
 BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR,
 CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES,
 ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN,
 IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC,
 LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX,
 MZ, MZ, NA, NI
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
 BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
 MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, ML, MR, NE, SN, TD, TG

WO 2004074246 A2 20040902 WO 2004-US4449 20040213
 W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG,
 BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR,
 CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES,
 ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN,
 IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC,
 LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX,
 MZ, MZ, NA, NI
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
 BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
 MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2003-447843P P 20030214
 US 2003-467035P P 20030501

GI



AB Title compds. I [R1 (taken 0-3 times) = alk(en/yn)yl, cycloalkyl, etc.; R2 (taken 0-3 times) = alk(en/yn)yl, cycloalkyl, CN, etc.; W = O, substituted N; R3 (taken 0-4 times) = alk(en/yn)yl, cycloalkyl, etc.; R4 = divalent group; R5 = H, alkyl; R6 = amino, alkoxy, etc.; R7 = H, etc.] are prepared For instance, N-[1,1'-Biphenyl-2-yl]-N'-[1-(9-aminononyl)piperidin-4-yl]urea (preparation given) is combined with 8-Benzyloxy-5-(2,2-dihydroxyacetyl)-1H-quinolin-2-one (CH₂Cl₂, NaHB(OAc)₃) and the product reduced (MeOH, H₂-Pd/C) to give II. Selected example compds. have K_i < 10 nM for the β₂ and **muscarinic receptor**. I are useful in the treatment of pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.

L8 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN.

ACCESSION NUMBER: 2003:656585 CAPLUS

DOCUMENT NUMBER: 139:197373

TITLE: Nicotinamide PDE4 inhibitors in combination with tiotropium **muscarinic receptor** antagonists for treating inflammatory, allergic and respiratory diseases

INVENTOR(S): Bailey, Simon; Gautier, Elisabeth Colette Louise; Henderson, Alan John; Mathias, John Paul; McLeod, Dale Gordon; Monaghan, Sandra Marina; Stammen, Blanda Luzia Christa

PATENT ASSIGNEE(S): Pfizer Limited, UK; Magee, Thomas Victor; Marfat, Anthony; Pfizer Inc.; et al.

SOURCE: PCT Int. Appl., 254 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068233	A1	20030821	WO 2003-IB378	20030203

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
 UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
 NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
 ML, MR, NE, SN, TD, TG

US 2003220361	A1	20031127	US 2003-360100	20030206
US 2003220366	A1	20031127	US 2003-361062	20030206
PRIORITY APPLN. INFO.:			GB 2002-3196	A 20020211
			GB 2002-20984	A 20020910
			GB 2002-24454	A 20021021
			GB 2002-27140	A 20021120
			US 2002-361991P	P 20020305
			GB 2002-20999	A 20020910
			US 2002-414247P	P 20020926
			US 2002-414304P	P 20020926
			GB 2002-24453	A 20021021
			US 2002-425406P	P 20021112
			US 2002-425474P	P 20021112
			GB 2002-27139	A 20021120
			US 2002-433330P	P 20021213
			US 2002-433336P	P 20021213

OTHER SOURCE(S): MARPAT 139:197373
 GI



I

AB The invention relates to a combination of nicotinamides (shown as I; variables defined below; e.g. anti-2-(benzo[1,3]dioxol-5-yloxy)-N-[4-(2-hydroxybenzoylamino)cyclohexyl]nicotinamide) and tiotropium or a derivative thereof, compns. containing them and the uses of, such combinations. The nicotinamide derivs. according to the present invention are phosphodiesterase-4 inhibitors and are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic, respiratory diseases, disorders and conditions, as well as wounds. For I: R1 and R2 = H, halo, cyano, (C1-C4)alkyl and (C1-C4)alkoxy; X is -O-, -S- or -NH-; R3 = Ph, naphthyl, heteroaryl and (C3-C8)cycloalkyl or the bicyclic groups benzodioxol-5-yl, benzofuran-5-yl, benzofuran-6-yl, indan-5-yl; Y = 4-HNcyclohexyl, piperidin-1,4-diyl, 8-azabicyclo[3.2.1]octane-3,8-diyl, and 4-R5Ncyclohexyl wherein in each the N is bonded to Z in I and R5 = (C1-C4)alkyl and phenyl(C1-C4)alkyl. Z = C(O), C(O)NH, SO2, SO2NH, C(O)CH2NHSO2, SO2NHC(O), C(O)CH2NHC(O) wherein the left end is bonded to Y and the other end to R4; or alternatively Y-Z together = 4-NHC(O)cyclohexyl; R4 = Ph, naphthyl heteroaryl and (C3-C8)cycloalkyl, (un)substituted (C1-C6)alkyl; addnl. details including provisos are given in the claims. The antiinflammatory properties of 72 examples of I are demonstrated by their ability to inhibit TNF α release from human peripheral blood mononuclear cells, e.g. IC50 = 0.014 nM for syn-2-(3,4-difluorophenoxy)-5-fluoro-N-[4-(2-hydroxy-5-methylbenzoylamino)cyclohexyl]nicotinamide. About 200 example preps. of I and 75 of intermediates, the same as in WO 03/068235 A1, are included.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

L8 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:506580 CAPLUS
DOCUMENT NUMBER: 139:79178
TITLE: Synthesis of 3H-pyrrolo[2,3-d]pyrimidine derivatives
and use as phosphodiesterase VII inhibitors and in
combination with other agents
INVENTOR(S): Eggenweiler, Hans-Michael; Wolf, Michael
PATENT ASSIGNEE(S): Merck Patent GmbH, Germany
SOURCE: Ger. Offen., 36 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10163991	A1	20030703	DE 2001-10163991	20011224
WO 2003055882	A1	20030710	WO 2002-EP12533	20021108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1458722	A1	20040922	EP 2002-805744	20021108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRIORITY APPLN. INFO.:			DE 2001-10163991	A 20011224
			WO 2002-EP12533	W 20021108

OTHER SOURCE(S): MARPAT 139:79178



AB The invention concerns the synthesis of 3H-pyrrolo[2,3-d]pyrimidine
derivs., their physiol. acceptable salts, stereoisomers, solvates, mixts.
thereof and their use as phosphodiesterase VII inhibitors in the treatment
of diseases that are influenced by the phosphodiesterase VII regulation of
human eosinophil activation and degradation. Osteoporosis, tumors,
cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis,
diabetes mellitus, AIDS, autoimmune and heart diseases can be treated with
the drugs. Thus the synthesis of 5-isopropyl-4-oxo-7-p-tolyl-4,7-dihydro-
3H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid Et ester and analog compds.
is described along with injection, suppository, tablet and other
formulations.

L8 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:396843 CAPLUS
DOCUMENT NUMBER: 138:401502
TITLE: Preparation of aryl aniline β -2 adrenergic
receptor agonists
INVENTOR(S): Moran, Edmund J.; Jacobsen, John R.; Leadbetter,
Michael R.; Nodwell, Matthew B.; Trapp, Sean G.;
Aggen, James; Church, Timothy J.
PATENT ASSIGNEE(S): Theravance, Inc, USA
SOURCE: PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003042164	A1	20030522	WO 2002-US36237	20021112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG EP 1446379 A1 20040818 EP 2002-780622 20021112 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK US 2004059116 A1 20040325 US 2003-642926 20030818 PRIORITY APPLN. INFO.: US 2001-338194P P 20011113 US 2001-343771P P 20011228 US 2002-292211 A1 20021112 WO 2002-US36237 W 20021112				
OTHER SOURCE(S): MARPAT 138:401502				
GI				



AB Title compds. I [R1-5 = H, alk(en/yn)yl, cycloalkyl, heterocyclyl, etc.;
 R6 = H, alkyl, alkoxy; R7 = H, alkyl; R8 = H, alkyl; R9 = alk(en/yn)yl, -
 (hetero)aryl, etc.; R10 = H, alkyl; R11-13 = H, (cyclo)alkyl, alkenyl,

alkynyl, (hetero)aryl, etc.; p = 0-4] are prepared For instance, the di-Me ketal of 4-hydroxy-3-hydroxymethyl- α -bromoacetophenone (preparation given) is reacted with 4-bromophenethylamine (CH₂Cl₂, Et₃N) followed by 4,4'-dimethoxychlorodiphenylamine and subsequently reduced (THF, NaBH₄). The resulting protected amino alc. is then coupled with N-(4-heptyl-6-methyl-2-pyrimidinyl)sulfanilamide (PhMe, dppf, Pd₂dba₃, 80°, 5 h) and then deprotected with HOAc (80°, 5 h) to give

II. All of the compds. tested demonstrated greater binding at the β ₂ adrenergic **receptor** than at the β ₁ adrenergic

receptor, i.e., $K_i(\beta_1) > K_i(\beta_2)$; many with a selectivity

greater than 20. I are useful for the treatment of pulmonary diseases.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:396839 CAPLUS

DOCUMENT NUMBER: 138:401501

TITLE: Preparation of aryl aniline β -2 adrenergic **receptor** agonists

INVENTOR(S): Moran, Edmund J.; Jacobsen, John R.; Aggen, James

PATENT ASSIGNEE(S): Theravance, Inc., USA

SOURCE: PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003042160	A1	20030522	WO 2002-US36188	20021112
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003153597	A1	20030814	US 2002-292211	20021112
US 6653323	B2	20031125		
US 2004059116	A1	20040325	US 2003-642926	20030818
PRIORITY APPLN. INFO.:			US 2001-338194P	P 20011113
			US 2002-292211	A1 20021112

OTHER SOURCE(S): MARPAT 138:401501

GI



I



II

AB Title compds. I [R1 = methoxy, ethoxy; R2 = H, Ph or R1 = H and R2 = phenyl; R3 = CH2OH, NHCHO; R4 = H or R3-4 = taken together are NHC(O)CH=CH] are prepared For instance, the di-Me ketal of 4-hydroxy-3-hydroxymethyl- α -bromoacetophenone (preparation given) is reacted with 4-bromophenethylamine (CH2Cl2, Et3N) followed by 4,4'-dimethoxychlorodiphenylamine and subsequently reduced (THF, NaBH4). The resulting protected amino alc. is then coupled with 4-methoxy-3-phenylaniline (PhMe, dppf, Pd2dba3, NaOBu-t, 80°, 5 h) and then deprotected with HOAc (80°, 5 h) to give II. All of the compds. tested demonstrated greater binding at the β 2 adrenergic **receptor** than at the β 1 adrenergic **receptor**, i.e., $K_i(\beta 1) > K_i(\beta 2)$; many with a selectivity greater than 20. I are useful for the treatment of pulmonary diseases.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:282532 CAPLUS

DOCUMENT NUMBER: 138:287681

TITLE: Preparation of heteroaryl substituted tetrazole modulators of metabotropic glutamate **receptor**
-5

INVENTOR(S): Cosford, Nicholas D.; Roppe, Jeffrey; Chen, Chixu; Smith, Nicholas; Reger, Thomas

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 119 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003029210	A2	20030410	WO 2002-US31294	20021001
WO 2003029210	A3	20031120		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1434773 A2 20040707 EP 2002-776076 20021001

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

WO 2004030637 A2 20040415 WO 2003-US9717 20030331

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM


RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2001-327132P	P 20011004
WO 2002-US31294	W 20021001
WO 2002-US40147	A 20021213
WO 2002-US41720	A 20021213
WO 2002-US40237	A 20021216
WO 2002-US40486	A 20021217

OTHER SOURCE(S):
GI

MARPAT 138:287681



AB Title compds. I [X, Y = (un)substituted (hetero)aryl; A, B = alkyl, alkyl-SO-alkyl, alkyl-SO₂-alkyl, etc.] are prepared For instance, 2-formylpyridine is condensed with toluenesulfonyl hydrazide to form the hydrazone. 3-Chloroaniline is converted to the diazonium salt and reacted with the hydrazone to form 2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]pyridine (II) as a pale orange solid. Compds. of the invention have IC₅₀ < 10μM for mGluR5 in the calcium flux assay. I are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other diseases.

L8 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:832576 CAPLUS

DOCUMENT NUMBER: 137:346197

TITLE: Treatment of respiratory and lung diseases with antisense oligonucleotides and a bronchodilating agent

INVENTOR(S): Nyce, Jonathan W.; Li, Yukui; Sandrasagra, Anthony;

PATENT ASSIGNEE(S): Katz, Evan; Pabalan, Jonathan; Aguilar, Douglas;
 SOURCE: Miller, Shoreh; Tang, Lei; Shahabuddin, Syed
 Epigenesis Pharmaceuticals, Inc., USA
 PCT Int. Appl., 764 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085309	A2	20021031	WO 2002-US13143	20020423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004049022	A1	20040311	US 2003-627930	20030725
PRIORITY APPLN. INFO.:				
			US 2001-286036P	P 20010424
			WO 2002-US13135	A2 20020423
			WO 2002-US13143	A2 20020423

OTHER SOURCE(S): MARPAT 137:346197

AB This patent relates to a composition comprising a carrier, oligonucleotides (oligos) that are antisense to adenosine receptors, and contain low amts. of or no adenosine (A), plus bronchodilating agents. All antisense oligonucleotides designed in accordance with the invention were highly effective at countering or reducing effects mediated by the receptors to which they are targeted. Two antisense phosphorothioated oligos targeting human adenosine A1 **receptor** mRNA, one targeting adenosine A2b **receptor**, and two targeting an A3 **receptor** are capable of countering the effect of exogenously administered adenosine which is mediated by the specific **receptor** they are targeted to. The activity of the antisense oligos are specific to the target and substitutively fail to inhibit another target. An oligonucleotide wherein the phosphodiester bonds are substituted with phosphorothioate bonds evidenced an unexpected superiority over the phosphodiester antisense oligo. In addition, they result in extremely low or non-existent deleterious side effects or toxicity. This represents 100% success in providing agents that are highly effective and specific in the treatment of bronchoconstriction and/or inflammation. These agents and the composition and formulations provided are suitable for the treatment of respiratory tract, pulmonary and malignant diseases associated with bronchoconstriction, respiratory tract inflammation and allergies, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject, such as allergies, asthma, impeded respiration, allergic rhinitis, pain, cystic fibrosis, pulmonary fibrosis, RDA, COPD, and cancers, among others. The present agents and composition may be administered preventatively, prophylactically or therapeutically in conjunction with other therapies, or may be utilized as a substitute for therapies that have significant, neg. side effects. The method of the present invention is also practiced with antisense oligonucleotides targeted to many genes, mRNAs and their corresponding proteins in essential the same manner.

L8 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:832575 CAPLUS
 DOCUMENT NUMBER: 137:346196

TITLE: Treatment of respiratory and lung diseases with
antisense oligonucleotides and a bronchodilating agent
INVENTOR(S): Nyce, Jonathan W.; Li, Yukui; Sandrasagra, Anthony;
Katz, Evan; Pabalan, Jonathan; Aguilar, Douglas;
Miller, Shoreh; Tang, Lei; Shahabuddin, Syed
PATENT ASSIGNEE(S): Epigenesis Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 872 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085308	A2	20021031	WO 2002-US13135	20020423
WO 2002085308	A3	20021219		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002085308	A2	20021031	WO 2002-XA13135	20020423
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002085308	A2	20021031	WO 2002-XB13135	20020423
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002085308	A2	20021031	WO 2002-XC13135	20020423
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004049022	A1	20040311	US 2003-627930	20030725
PRIORITY APPLN. INFO.:			US 2001-286137P	P 20010424

OTHER SOURCE(S): MARPAT 137:346196

AB This patent relates to a composition comprising a carrier, oligonucleotides (oligos) that are antisense to adenosine receptors, and contain low amts. of or no adenosine (A), plus bronchodilating agents. All antisense oligonucleotides designed in accordance with the invention were highly effective at countering or reducing effects mediated by the receptors to which they are targeted. Two antisense phosphorothioated oligos targeting human adenosine A1 **receptor** mRNA, one targeting adenosine A2b **receptor**, and two targeting an A3 **receptor** are capable of countering the effect of exogenously administered adenosine which is mediated by the specific **receptor** they are targeted to. The activity of the antisense oligos are specific to the target and substitutively fail to inhibit another target. An oligonucleotide wherein the phosphodiester bonds are substituted with phosphorothioate bonds evidenced an unexpected superiority over the phosphodiester antisense oligo. In addition, they result in extremely low or non-existent deleterious side effects or toxicity. This represents 100% success in providing agents that are highly effective and specific in the treatment of bronchoconstriction and/or inflammation. Treatment with antisense oligonucleotides in combination with anti-inflammatory steroid and/or ubiquinones is also provided. These agents and the composition and formulations provided are suitable for the treatment of respiratory tract, pulmonary and malignant diseases associated with bronchoconstriction, respiratory tract inflammation and allergies, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject, such as allergies, asthma, impeded respiration, allergic rhinitis, pain, cystic fibrosis, pulmonary fibrosis, RDA, COPD, and cancers, among others. The present agents and composition may be administered preventatively, prophylactically or therapeutically in conjunction with other therapies, or may be utilized as a substitute for therapies that have significant, neg. side effects. The method of the present invention is also practiced with antisense oligonucleotides targeted to many genes, mRNAs and their corresponding proteins in essentially the same manner.

L8 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:609823 CAPLUS

DOCUMENT NUMBER: 136:95912

TITLE: NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors

AUTHOR(S): Braun, Kirsten; Rettinger, Jurgen; Ganso, Matthias; Kassack, Matthias; Hildebrandt, Caren; Ullmann, Heiko; Nickel, Peter; Schmalzing, Gunther; Lambrecht, Gunter

CORPORATE SOURCE: Biocentre Niederursel, Department of Pharmacology, University of Frankfurt, Frankfurt/Main, 60439, Germany

SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology (2001), 364(3), 285-290

CODEN: NSAPCC; ISSN: 0028-1298

PUBLISHER: Springer-Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Antagonistic effects of the novel suramin analog 4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid (NF449) were studied on contractions of the rat vas deferens elicited by α,β -methylene ATP ($\alpha\beta$ meATP; mediated by P2X1 receptors), contractions of the guinea-pig ileal longitudinal smooth muscle elicited by $\alpha\beta$ meATP (mediated by P2X3 receptors) or adenosine 5'-O-(2-thiodiphosphate) (ADP β S; mediated by P2Y1 receptors), ATP-induced increases of [Ca²⁺]_i in human embryonic kidney (HEK) 293 cells (mediated by P2Y2 receptors), inward

currents evoked by ATP in follicle cell-free *Xenopus laevis* oocytes expressing rP2X1 or rP2X3 receptors and degradation of ATP by ecto-nucleotidases in folliculated *Xenopus laevis* oocytes. In addition, NF449 was examined for its P2 **receptor** specificity in rat vas deferens (α 1A-adrenoceptors) and guinea-pig ileum (histamine H1 and **muscarinic** M3 receptors). At native (pIC₅₀=7.15) and recombinant (pIC₅₀=9.54) P2X1 receptors, NF449 was a highly potent antagonist. The P2X3 receptors present in guinea-pig ileum (pIC₅₀=5.04) or expressed in oocytes (pIC₅₀≈5.6) were much less sensitive for NF449. It also was a very weak antagonist at P2Y1 receptors in guinea-pig ileum (pIC₅₀=4.85) and P2Y2 receptors in HEK 293 cells (pIC₅₀=3.86), and showed very low inhibitory potency on ecto-nucleotidases (pIC₅₀<3.5). NF449 (100 μ M) did not interact with α 1A-adrenoceptors or histamine H1 and **muscarinic** M3 receptors. Thus, the antagonism by NF449 is highly specific for P2 receptors. In conclusion, the subnanomolar potency at rP2X1 receptors and the rank order of potency, P2X1 >> P2X3 > P2Y1 > P2Y2 > ecto-nucleotidases, make NF449 unique among the P2 **receptor** antagonists reported to date. NF449 may fill the long-standing need for a P2X1-selective radioligand.

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:832187 CAPLUS

DOCUMENT NUMBER: 134:147471

TITLE: A potent, long-acting, orally active (2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: a novel **muscarinic** M3 **receptor** antagonist with high selectivity for M3 over M2 receptors

AUTHOR(S): Mitsuya, Morihiro; Kobayashi, Kensuke; Kawakami, Kumiko; Satoh, Atsushi; Ogino, Yoshio; Kakikawa, Taro; Ohtake, Norikazu; Kimura, Toshifumi; Hirose, Hiroyasu; Sato, Akio; Numazawa, Tomosige; Hasegawa, Takuro; Noguchi, Kazuhito; Mase, Toshiaki

CORPORATE SOURCE: Banyu Tsukuba Research Institute in Collaboration with Merck Research Laboratories, Tsukuba, Ibaraki, 300-2611, Japan

SOURCE: Journal of Medicinal Chemistry (2000), 43(26), 5017-5029


CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society


DOCUMENT TYPE: Journal

LANGUAGE: English


GI



I



II



III

AB A novel series of (2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamides I (R = CH₂Ph, 3-furylmethyl, 2-pyridyl, etc.) and II (R = 2-MeC₆H₄CH₂, cyclohexylmethyl, 3-pyridylmethyl, etc.) was designed and synthesized based on the structure and biol. profiles of an active metabolite III (R = OH) of the prototype **muscarinic M3 receptor** selective antagonist III (R = H), to develop a potent, long-acting, orally active M3 antagonist for the treatment of urinary tract disorders, irritable bowel syndrome, and respiratory disorders. Investigation of I [R = (substituted phenyl)methyl, (substituted pyridyl)methyl, (substituted thienyl)methyl] containing a Ph or heterocyclic ring as the piperidinyl side chain in place of the 4-methyl-3-pentenyl moiety of I (R = 4-Me-3-pentenyl) revealed that this acid moiety was a versatile template for improving the selectivity for M3 over M2 receptors in comparison with the corresponding cyclopentylphenylacetic acid group. However, since the in vitro metabolic stability of these analogs was insufficient compared with that of III (R = OH), further derivatization was performed by introducing an appropriate hydrophilic group into the Ph or 2-pyridyl ring. Thus, the 1-(6-aminopyridin-2-ylmethyl)piperidine analog I (R = 6-amino-2-pyridylmethyl) exhibiting 190-fold selectivity for M3 receptors (K_i = 2.8 nM) over M2 receptors (K_i = 530 nM) in a human binding assay and good in vitro metabolic stability in dog and human hepatic microsomes was identified. This compound has excellent oral activity at 4 h after oral dosing (1 mg/kg), inhibiting methacholine-induced bronchoconstriction in dogs, and may be useful in clin. situations in which M3 over M2 selectivity is desirable.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 20:38:41 ON 23 SEP 2004)

FILE 'REGISTRY' ENTERED AT 20:39:05 ON 23 SEP 2004

L1 STRUCTURE UPLOADED
L2 50 S SAM L1

L3 62637 S L1 FULL

FILE 'CAPLUS' ENTERED AT 20:48:04 ON 23 SEP 2004

L4 771 S L3 AND RECEPTOR

L5 73 S L4 AND LIGAND

L6 5 S L5 AND (DIVALENT OR MULTIVALENT OR DIMERIC OR MULTIMERIC OR M

L7 12 S L4 AND G (3W) PROTEIN

FILE 'STNGUIDE' ENTERED AT 21:01:25 ON 23 SEP 2004

FILE 'CAPLUS' ENTERED AT 21:02:16 ON 23 SEP 2004

L8 10 S L4 AND MUSCARINIC

=> s 15 not 16

L9 68 L5 NOT L6

=> s 19 not 17

L10 64 L9 NOT L7

=> s 110 not 18

L11 61 L10 NOT L8

=> t ti 111 1-30

L11 ANSWER 1 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN

TI Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate **receptor** antagonists

L11 ANSWER 2 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN

TI [3H]A-317491, a novel high-affinity non-nucleotide antagonist that specifically labels human P2X2/3 and P2X3 receptors

L11 ANSWER 3 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN

TI Dye-Labeled Benzodiazepines: Development of Small Ligands for **Receptor** Binding Studies Using Fluorescence Correlation Spectroscopy

L11 ANSWER 4 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN

TI Fluorescent ligands and measuring of binding of samples to androgen **receptor**

L11 ANSWER 5 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN

TI Preparation of 4-(phenylpiperazinylmethyl)benzamides for treatment of pain or gastrointestinal disorders

L11 ANSWER 6 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN

TI Ligands for the peroxisome proliferator-activated **receptor**

L11 ANSWER 7 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN

TI Preparation of a novel diphosphine-palladium macrocyclic complex possessing a molecular recognition site. Oxidative addition studies

L11 ANSWER 8 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN

TI Rational Design and Synthesis of Androgen **Receptor**-Targeted Nonsteroidal Anti-Androgen Ligands for the Tumor-Specific Delivery of a Doxorubicin-Formaldehyde Conjugate

L11 ANSWER 9 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN

TI 2', 3'-O-(2,4,6, trinitrophenyl)-ATP and A-317491 are competitive antagonists at a slowly desensitizing chimeric human P2X3 **receptor**

- L11 ANSWER 10 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of pyridones as modulators of nuclear receptors, including liver X **receptor** (LXR).
- L11 ANSWER 11 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN
TI Novel fluorescence based **receptor** binding assay method for receptors lacking **ligand** conjugates with preserved affinity: Study on estrogen **receptor** α
- L11 ANSWER 12 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN
TI A novel strapped porphyrin **receptor** for molecular recognition
- L11 ANSWER 13 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN
TI Synthetic Inhibitors of Proline-Rich **Ligand**-Mediated Protein-Protein Interaction: Potent Analogs of UCS15A
- L11 ANSWER 14 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of piperidino cannabinoid **receptor** ligands
- L11 ANSWER 15 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of benzotriazepines as gastrin and cholecystokinin **receptor** ligands for treating gastrointestinal disorders
- L11 ANSWER 16 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN
TI Exponential pattern recognition-based cellular targeting, compositions, methods and anticancer applications
- L11 ANSWER 17 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN
TI Synthesis and Investigation of New Macrocyclic Diphosphine-Palladium(0) Complexes Based on the Barbiturate Binding **Receptor**
- L11 ANSWER 18 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN
TI Anion-Templated Rotaxane Formation
- L11 ANSWER 19 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN
TI Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABAA **receptor**
- L11 ANSWER 20 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN
TI Environment and mobility of a series of fluorescent reporters at the amino terminus of structurally related peptide agonists and antagonists bound to the cholecystokinin **receptor**
- L11 ANSWER 21 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of naphthalene derivatives as cannabinoid CB1 **receptor** ligands.
- L11 ANSWER 22 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN
TI Comparative binding energy (COMBINE) analysis of human neutrophil elastase inhibition by pyridone-containing trifluoromethylketones
- L11 ANSWER 23 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation and formulation of imidazoles as gastrin and cholecystokinin **receptor** ligands for treatment of gastrointestinal disorders
- L11 ANSWER 24 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation and pharmaceutical compositions of gastrin/cholecystokinin **receptor** ligands with proton pump inhibitors
- L11 ANSWER 25 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN
TI Analysis of fluorescently labeled substance P analogs: binding, imaging

and **receptor** activation

L11 ANSWER 26 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN
TI Validation of flow cytometric competitive binding protocols and
characterization of fluorescently labeled ligands

L11 ANSWER 27 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN
TI Therapeutic uses of PPAR mediators as ABC-1 expression modulators, and
preparation thereof

L11 ANSWER 28 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN
TI Synthesis and characterization of new aromatic tweezers and complex
formation with tropylium ion in 1,2-dichloroethane

L11 ANSWER 29 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of 4-(arylhydroxyethylaminoethyl)phenylaminohydroxyethylbenzen
es and related compounds as β 2 adrenergic **receptor** agonists
and partial agonists.

L11 ANSWER 30 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN
TI Nonpeptide cholecystokinin-2 **receptor** agonists

=> d his

(FILE 'HOME' ENTERED AT 20:38:41 ON 23 SEP 2004)

FILE 'REGISTRY' ENTERED AT 20:39:05 ON 23 SEP 2004

L1 STRUCTURE UPLOADED
L2 50 S SAM L1
L3 62637 S L1 FULL

FILE 'CAPLUS' ENTERED AT 20:48:04 ON 23 SEP 2004

L4 771 S L3 AND RECEPTOR
L5 73 S L4 AND LIGAND
L6 5 S L5 AND (DIVALENT OR MULTIVALENT OR DIMERIC OR MULTIMERIC OR M
L7 12 S L4 AND G (3W) PROTEIN

FILE 'STNGUIDE' ENTERED AT 21:01:25 ON 23 SEP 2004

FILE 'CAPLUS' ENTERED AT 21:02:16 ON 23 SEP 2004

L8 10 S L4 AND MUSCARINIC
L9 68 S L5 NOT L6
L10 64 S L9 NOT L7
L11 61 S L10 NOT L8

=> s l11 and py>1998

5458940 PY>1998

L12 46 L11 AND PY>1998

=> s l11 not l12

L13 15 L11 NOT L12

=> d scan l13

L13 15 ANSWERS CAPLUS COPYRIGHT 2004 ACS on STN
CC 1-6 (Pharmacology)
TI Antimetastatic activities of synthetic Arg-Gly-Asp-Ser (RGDS) and
Arg-Leu-Asp-Ser (RLDS) peptide analogs and their inhibitory mechanisms
ST antitumor metastasis RGDS RLDS peptide
IT Basement membrane
Extracellular matrix

(inhibitory effect of the N-terminal modified Arg-Gly-Asp-Ser analogs on tumor cell adhesion and antimetastatic activity)

IT Fibronectins
Integrins
Laminins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(inhibitory effect of the N-terminal modified Arg-Gly-Asp-Ser analogs on tumor cell adhesion and antimetastatic activity)

IT Adhesion
(bio-, inhibitory effect of the N-terminal modified Arg-Gly-Asp-Ser analogs on tumor cell adhesion and antimetastatic activity)

IT Neoplasm inhibitors
(liver, metastasis, inhibitory effect of the N-terminal modified Arg-Gly-Asp-Ser analogs on tumor cell adhesion and antimetastatic activity)

IT Neoplasm inhibitors
(lung, metastasis, inhibitory effect of the N-terminal modified Arg-Gly-Asp-Ser analogs on tumor cell adhesion and antimetastatic activity)

IT Neoplasm inhibitors
(metastasis, antimetastatic activities of synthetic Arg-Gly-Asp-Ser (RGDS) and Arg-Leu-Asp-Ser (RLDS) peptide analogs and their inhibitory mechanisms)

IT Liver, neoplasm
Lung, neoplasm
(metastasis, inhibitors, inhibitory effect of the N-terminal modified Arg-Gly-Asp-Ser analogs on tumor cell adhesion and antimetastatic activity)

IT Animal growth regulators
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(vitronectins, inhibitory effect of the N-terminal modified Arg-Gly-Asp-Ser analogs on tumor cell adhesion and antimetastatic activity)

IT 91037-65-9P 150525-67-0P 151997-55-6P **161115-64-6P**
161189-78-2P 173737-87-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antimetastatic activities of synthetic Arg-Gly-Asp-Ser (RGDS) and Arg-Leu-Asp-Ser (RLDS) peptide analogs and their inhibitory mechanisms)

IT 7536-58-5P 160541-40-2P 161189-80-6P 173737-85-4P
173737-86-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(antimetastatic activities of synthetic Arg-Gly-Asp-Ser (RGDS) and Arg-Leu-Asp-Ser (RLDS) peptide analogs and their inhibitory mechanisms)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L13 15 ANSWERS CAPLUS COPYRIGHT 2004 ACS on STN
CC 25-17 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1
TI Synthesis and Characterization of a Highly Potent and Selective Isotopically Labeled Retinoic Acid **Receptor Ligand**, ALRT1550
ST ALRT1550 labeled analogs prepn **receptor** binding; retinoic acid **receptor** binding labeled ALRT1550
IT Retinoic acid receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(isotopically labeled retinoic acid **receptor ligand**
ALRT1550)

IT 302-79-4, all-trans-Retinoic acid 71441-28-6, TTNPB
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(isotopically labeled retinoic acid **receptor ligand**
ALRT1550)

IT 178600-20-9P, ALRT1550 200556-30-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(isotopically labeled retinoic acid **receptor ligand**
ALRT1550)

IT 2359-09-3, 1,3-Benzenedicarboxylic acid, 5-(1,1-dimethylethyl)-
16225-26-6, 3,5-Di-tert-butylbenzoic acid 41891-54-7 50917-73-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(isotopically labeled retinoic acid **receptor ligand**
ALRT1550)

IT 22157-91-1P, 1,3-Benzenedimethanol, 5-(1,1-dimethylethyl)- 178688-27-2P
180740-53-8P, 1,3-Benzenedimethanol, 5-(1,1-dimethylethyl)-
 α,α' -dimethyl- **180740-54-9P** 180740-55-0P
180740-56-1P 180740-57-2P 180740-58-3P 180740-59-4P 180740-60-7P
180740-61-8P 180740-62-9P 180740-63-0P 180740-64-1P 180740-69-6P,
1,3-Benzenedicarboxaldehyde, 5-(1,1-dimethylethyl)- 200556-34-9P
200556-36-1P 200556-38-3P 200556-39-4P 200556-41-8P 200556-61-2P
200556-63-4P 200556-64-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(isotopically labeled retinoic acid **receptor ligand**
ALRT1550)

IT 200556-27-0P 200556-44-1P 200556-45-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(isotopically labeled retinoic acid **receptor ligand**
ALRT1550)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> d his

(FILE 'HOME' ENTERED AT 20:38:41 ON 23 SEP 2004)

FILE 'REGISTRY' ENTERED AT 20:39:05 ON 23 SEP 2004

L1 STRUCTURE UPLOADED
L2 50 S SAM L1
L3 62637 S L1 FULL

FILE 'CAPLUS' ENTERED AT 20:48:04 ON 23 SEP 2004

L4 771 S L3 AND RECEPTOR
L5 73 S L4 AND LIGAND
L6 5 S L5 AND (DVALENT OR MULTIVALENT OR DIMERIC OR MULTIMERIC OR M
L7 12 S L4 AND G (3W) PROTEIN

FILE 'STNGUIDE' ENTERED AT 21:01:25 ON 23 SEP 2004

FILE 'CAPLUS' ENTERED AT 21:02:16 ON 23 SEP 2004

L8 10 S L4 AND MUSCARINIC
L9 68 S L5 NOT L6
L10 64 S L9 NOT L7
L11 61 S L10 NOT L8
L12 46 S L11 AND PY>1998
L13 15 S L11 NOT L12

=> d ibib abs 113

L13 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:447028 CAPLUS
DOCUMENT NUMBER: 129:221600
TITLE: Molecular Recognition on Functionalized Self-Assembled Monolayers of Alkanethiols on Gold
AUTHOR(S): Moteshareei, Kianoush; Myles, David C.
CORPORATE SOURCE: Department of Chemistry Biochemistry, University of California, Los Angeles, CA, 90095-1569, USA
SOURCE: Journal of the American Chemical Society (1998), 120(29), 7328-7336
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A system for probing mol. recognition events at organic interfaces using fluorescent receptors is described. Receptors formed from the bis(2,6-diaminopyridine) amide of isophthalic acid are incorporated in mixed self-assembled monolayers (SAMs) of alkanethiols on gold and shown to interact with barbituric acid derivs. from solution Individual parameters that affect the ability of receptors on surfaces to recognize ligands from solution along with varieties of solvents for **ligand** solns. were examined

REFERENCE COUNT: 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs 113 2-15

L13 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:437199 CAPLUS
DOCUMENT NUMBER: 129:213752
TITLE: The use of affinity capillary electrophoresis for determining binding constants of ligands to receptors
AUTHOR(S): Zhao, Dong S.; Kwak, Eun-Soo; Kawaoka, Jane; Esquivel, Sally; Gomez, Frank A.
CORPORATE SOURCE: Univ. California, Riverside, CA, USA
SOURCE: American Laboratory (Shelton, Connecticut) (1998), 30(12), 40, 42-47
CODEN: ALBYBL; ISSN: 0044-7749
PUBLISHER: International Scientific Communications, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The paper reports on using affinity capillary electrophoresis (ACE) to determine binding consts. between three **receptor -ligand** combinations: carbonic anhydrase B and arylsulfonamides; vancomycin and the peptide N-acetyl-D-Ala-D-Ala; adamantane carboxylic acids and β -cyclodextrin derivs.

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:307721 CAPLUS
DOCUMENT NUMBER: 129:41403
TITLE: A trivalent system from vancomycin-D-Ala-D-Ala with higher affinity than avidin-biotin
AUTHOR(S): Rao, Jianghong; Lahiri, Joydeep; Isaacs, Lyle; Weis, Robert M.; Whitesides, George M.
CORPORATE SOURCE: Dep. Chem. Chem. Biol., Harvard Univ., Cambridge, MA, 02138, USA
SOURCE: Science (Washington, D. C.) (1998), 280(5364), 708-711

PUBLISHER: American Association for the Advancement of Science
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Tris(vancomycin carboxamide) binds a trivalent **ligand** derived from D-Ala-D-Ala with very high affinity: dissociation constant (K_d) $\approx 4 + 10^{-17} \pm 1 + 10^{-17}$ M. High-affinity trivalent binding and monovalent binding are fundamentally different. For example, in trivalent (and more generally, polyvalent) binding, dissociation occurs in stages, and its rate can be accelerated by monovalent **ligand** at sufficiently high concns. In monovalent binding, dissociation is determined solely by the rate

constant for dissociation and cannot be accelerated by added monomer. Calorimetric measurements for the trivalent system indicate an approx. additive gain in enthalpy relative to the corresponding monomers. This system is one of the most stable organic **receptor-ligand** pairs involving small mols. that is known. It illustrates the practicality of designing very high-affinity systems based on polyvalency.

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:48108 CAPLUS

DOCUMENT NUMBER: 128:75158

TITLE: Synthesis and Characterization of a Highly Potent and Selective Isotopically Labeled Retinoic Acid
Receptor Ligand, ALRT1550

AUTHOR(S): Bennani, Youssef L.; Marron, Kristin S.; Mais, Dale E.; Flatten, Karen; Nadzan, Alex M.; Boehm, Marcus F.

CORPORATE SOURCE: Departments of Medicinal Chemistry and Endocrine Research, Ligand Pharmaceuticals Inc., San Diego, CA, 92121, USA


SOURCE: Journal of Organic Chemistry (1998), 63(3), 543-550
CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I

AB The syntheses of two labeled homologs of (2E,4E,6E)-7-(3,5-di-tert-butylphenyl)-3-methylocta-2,4,6-trienoic acid [ALRT1550, I ($R_1 = H$, $R_2 = Me$)], namely, [$^{13}CD_3$]ALRT1550 (I; $R_1 = H$, $R_2 = ^{13}CD_3$) and [3H]ALRT1550 (I; $R_1 = ^3H$, $R_2 = Me$), are described. ALRT1550 is an exceptionally potent antiproliferative agent which is currently in phase I/II clin. trials for acute chemotherapy. Both homologs were prepared from com. available 3,5-di-tert-butylbenzoic acid. Homolog [$^{13}CD_3$]ALRT1550 was labeled at the 7-position of the trienoic acid chain via addition of [$^{13}CD_3$]MgI to a Weinreb amide precursor. The preparation of [3H]ALRT1550 utilized novel methodol. to prepare a sterically hindered and site-specific tritium-labeled tert-Bu group. Saturation binding and Scatchard anal. of this **ligand** at the

retinoic acid receptors are also described, along with competition binding (K_i) values for a series of known retinoids using [3H]ALRT1550 or [3H]ATRA as the labeled probes.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:719041 CAPLUS

DOCUMENT NUMBER: 126:74845

TITLE: Preparation of fluorescent **receptor** ligands

INVENTOR(S): McCabec, R. Tyler; Rhodes, Christopher A.; DeCosta, Bruce F.

PATENT ASSIGNEE(S): Pharmaceutical Discovery Corporation, USA

SOURCE: U.S., 21 pp., Cont.-in-part of U.S. Ser. No. 623,837, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5576436	A	19961119	US 1994-204559	19940302
PRIORITY APPLN. INFO.:			US 1991-739183	19910801
			US 1992-923837	19920731

GI



I



AB Title compds. comprise Conjugates of fluorescent labels with specific, selective, and high affinity ligands for receptors, e.g., NMDA, cannabinoid, glycine, etc. Thus, amine I (R = H) was amidated by fluorescein derivative R1R2 (R1 = fluorescein moiety Q, R2 = succinimidooxy) to give I (R = Q) as a κ1 opioid probe. Data for biol. activity of selected title compds. were given.

L13 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:681495 CAPLUS
DOCUMENT NUMBER: 126:26367
TITLE: Serotonin Dimers: Application of the Bivalent
Ligand Approach to the Design of New Potent
and Selective 5-HT1B/1D Agonists
AUTHOR(S): Halazy, Serge; Perez, Michel; Fourrier, Catherine;
Pallard, Isabelle; Pauwels, Petrus J.; Palmier,
Christiane; John, Gareth W.; Valentin, Jean-Pierre;
Bonnafous, Regine; Martinez, Jean
CORPORATE SOURCE: Medicinal Chemistry Division, Centre de Recherche
Pierre Fabre, Castres, 81106, Fr.
SOURCE: Journal of Medicinal Chemistry (1996), 39(25),
4920-4927
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A series of serotonin dimers in which two serotonin moieties are linked together through their 5-hydroxyl residue has been prepared and evaluated as 5-HT1B/1D **receptor** agonists. Binding expts. at cloned human 5-HT1B, 5-HT1D, and 5-HT1A receptors show that all of these dimers are very potent ligands at 5-HT1B/1D receptors with increased binding selectivity vs. the 5-HT1A **receptor** when compared to serotonin. Studies of inhibition of the forskolin-stimulated c-AMP formation mediated by the human 5-HT1B **receptor** (formerly the 5-HT1D β **receptor**) demonstrate that all of these serotonin dimers behave as full agonists. Among them, the piperazide derivs. of bis-serotonin, 4g,j, were also identified as very potent agonists in contracting the New Zealand white rabbit saphenous vein (pD₂ = 7.6 in each case compared to 5.8 for sumatriptan). Results anal. supports the hypothesis that the important increase in potency of the serotonin dimers can be attributed to the presence of two serotonin pharmacophores in the same mol., while the enhanced selectivity for 5-HT1B/1D **receptor** subtypes may be due to the position of the spacer attachment to serotonin.

L13 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:505199 CAPLUS
DOCUMENT NUMBER: 125:247557
TITLE: Halide anion recognition by new acyclic quaternary
polybipyridinium and polypyridinium receptors
AUTHOR(S): Beer, Paul D.; Fletcher, Nicolas C.; Grieve, Alan;
Wheller, John W.; Moore, Christopher P.; Wear, Trevor
CORPORATE SOURCE: Inorg. Chem. Lab., Univ. Oxford, Oxford, OX1 3QR, UK
SOURCE: Journal of the Chemical Society, Perkin Transactions
2: Physical Organic Chemistry (1996), (8), 1545-1552
CODEN: JCPKBH; ISSN: 0300-9580
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English

AB New acyclic quaternary polybipyridinium receptors containing 5,5'- and 4,4'-disubstituted N,N'-dimethyl-2,2'-bipyridinium moieties and a polypyridinium **receptor** have been synthesized. ¹H NMR titration studies in deuterated DMSO show that these receptors complex chloride and bromide anions, with a 1:1 stoichiometric **ligand:chloride** stability constant evaluations suggesting the amide containing polypyridinium **receptor** forms the most thermodyn. stable chloride anion complex. Square-wave voltammetric investigations showed some of the polypyridinium receptors to recognize electrochem. the chloride anion.

L13 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:25017 CAPLUS

DOCUMENT NUMBER: 124:164460
TITLE: Antimetastatic activities of synthetic Arg-Gly-Asp-Ser (RGDS) and Arg-Leu-Asp-Ser (RLDS) peptide analogs and their inhibitory mechanisms
AUTHOR(S): Fujii, Hideki; Komazawa, Hiroyuki; Mori, Hideto; Kojima, Masayoshi; Itoh, Isamu; Murata, Jun; Azuma, Ichiro; Saiki, Ikuro
CORPORATE SOURCE: Res. Inst. Wakan-Yaku, Toyama Med. and Pharmaceutical Univ., Toyama, 930-01, Japan
SOURCE: Biological & Pharmaceutical Bulletin (1995), 18(12), 1681-8
CODEN: BPBLEO; ISSN: 0918-6158
PUBLISHER: Pharmaceutical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We have investigated the inhibitory effect of the N-terminal modified Arg-Gly-Asp-Ser (RGDS) analogs, AcDRGDS and AcDRLDS, on tumor cell adhesion to the components of extracellular matrix and basement membrane, and also tested the antimetastatic effect of their conjugates with trimesic acid, Ar(DRGDS)3 and AR(DRLDS)3. AcDRGDS significantly inhibited tumor cell adhesion to fibronectin, vitronectin and RGDS substrates, but not to CS1 substrate which is a **ligand** for the $\alpha 4\beta 1$ tumor surfaces integrin **receptor**. In contrast, AcDRLDS variant peptide significantly inhibited tumor cell adhesion to laminin, in addition to RGDS-mediated adhesion to fibronectin and vitronectin. AcDRLDS also inhibited tumor cell adhesion to CS1 as well as the RGDS sequence within the fibronectin mol. in a concentration-dependent manner, although the inhibitory effect was less than that of the CS1 (EILDV) peptide. Ar(DRLDS)3 inhibited the laminin- and fibronectin-mediated invasion and migration of tumor cells, whereas Ar(DRGDS)3 inhibited the laminin- and fibronectin-mediated invasion and migration of tumor cells, whereas Ar(DRGDS)3 selectively inhibited exptl. lung or liver metastases of various types of murine and human tumors than the original RGDS-containing peptides or Ar(COONa)3. Multiple administrations of Ar(DRGDS)3 or Ar(DRLDS)3 potentially inhibited spontaneous lung metastasis produced by intra-footpad injection of B16-BL6 cells without affecting the primary tumor size at the time of surgical excision, as compared with RGDS peptide or untreated control. Thus, AR(DRGDS)3 and AR(DRLDS)3 substantially increased the exhibiting any antimetastatic effect of the peptides without direct cytotoxicity.

L13 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:44283 CAPLUS
DOCUMENT NUMBER: 122:71336
TITLE: Non-peptide fibrinogen **receptor** antagonists.
4. Proposed three-dimensional requirements in centrally constrained inhibitors
AUTHOR(S): Naylor, A. M.; Egbertson, M. S.; Vassallo, L. M.; Birchenough, L. A.; Zhang, G. X.; Gould, R. J.; Hartman, G. D.
CORPORATE SOURCE: Dep. Biol. Chem., Merck Res. Lab., West Point, PA, 19486, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (1994), 4(15), 1841-6
CODEN: BMCLE8; ISSN: 0960-894X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A three-dimensional description of **ligand** conformations consistent with GPIIb/IIIa antagonist activity was developed from a systematic conformational search of centrally-constrained fibrinogen **receptor** antagonists.

L13 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1994:503388 CAPLUS
DOCUMENT NUMBER: 121:103388
TITLE: Molecular Recognition in Membrane Mimics: A
Fluorescence Probe
AUTHOR(S): Motesharei, Kianoush; Myles, David C.
CORPORATE SOURCE: Department of Chemistry and Biochemistry, University
of California, Los Angeles, CA, 90024-1569, USA
SOURCE: Journal of the American Chemical Society (1994),
116(16), 7413-14
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A system is described for probing mol. recognition events in synthetic membranes using the change in the wavelength of fluorescence of receptors upon binding of **ligand**. The bis(2,6-diaminopyridine) amide of isophthalic acid was used as the **receptor**. Mixed monolayer containing receptors functionalized with 10-carbon alkanethiol tethers and octanethiol were self-assembled on thin films of gold. A series of fluorescence expts. demonstrated that the presence of **ligand** by the **receptor**. The key evidence for interaction of the **ligand** and **receptor** was the reversible shift of the wavelength of fluorescence emission of the **receptor** in the presence and absence of the **ligand**.

L13 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1993:251070 CAPLUS
DOCUMENT NUMBER: 118:251070
TITLE: Characterization of specific drug receptors with
fluorescent ligands, and fluorescent **ligand**
preparation
INVENTOR(S): McCabe, R. Tyler; Rhodes, Christopher A.
PATENT ASSIGNEE(S): Pharmaceutical Discovery Corp., USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 9303382	A2	19930218	WO 1992-US6447	19920731
WO 9303382	A3	19930429		
W: AU, CA, HU, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
AU 9224071	A1	19930302	AU 1992-24071	19920731
US 5468854	A	19951121	US 1993-95937	19930722
PRIORITY APPLN. INFO.:			US 1991-739183	19910801
			WO 1992-US6447	19920731

AB Conjugates of fluorescent labels with specific, selective, and high-affinity **receptor** ligands are prepared. The conjugates are used to directly measure binding to receptors (benzodiazepine receptors, opioid receptors, adrenergic receptors, K channels, etc.). The label portion of the conjugate may be fluorescein or derivative thereof, Texas red, coumarin, dansyl chloride, etc. Thus, **k1-opioid receptor** fluorescent probe 1S,2S-trans-4,5-dichloro-2-(4-fluorescein-5-carboxamido)-n-butanamido)-(N-methyl)-2-(1-pyrrolidinyl)-cyclohexyl)benzeneacetamide (preparation given) had an inhibitory constant vs. radioligand binding of 0.85 nM.

SOURCE: Molecular Neuropharmacology (1991), 1(3), 149-54
CODEN: MOLNEO; ISSN: 0959-5244
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A possible relation between the 3D-mol. electrostatic potential (MEP) distribution around the aromatic nucleus of phenylethanamines (both agonists and antagonist) and their intrinsic sympathomimetic activity (IA) is presented. MEPs are calculated at a distance of 1.5 Å from the van der Waals surface using the program package GAMESS at the ab initio LCAO-MO-SCF level invoking the STO3G minimal basis set. The most striking differences between agonists and antagonists occur in the region between the 4- and 5-position of the aromatic nucleus and to a lesser extent in the region around the 3- and 5-position. Agonists with a catechol-moiety form an intramol. hydrogen bond in which the substituent at the 3-position acts as hydrogen donor and the substituent at the 4-position as hydrogen acceptor. The inactivity of 6-halo substituted phenylethanamine derivs. is most likely due to the induction of an unfavorable electrostatic field around the β-hydroxyl substituent rather than to conformational factors.

L13 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1991:94515 CAPLUS
DOCUMENT NUMBER: 114:94515
TITLE: Characterization of benzodiazepine receptors with fluorescent ligands
AUTHOR(S): McCabe, R. Tyler; De Costa, Brian R.; Miller, Rachel L.; Havunjian, R. Hratchia; Rice, Kenner C.; Skolnick, Phil
CORPORATE SOURCE: Lab. Neurosci., Natl. Inst. Diabetes, Bethesda, MD, 20892, USA
SOURCE: FASEB Journal (1990), 4(11), 2934-40
CODEN: FAJOEC; ISSN: 0892-6638
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Fluorescein conjugates of the high-affinity benzodiazepine **receptor** ligands Ro 15-1788 and Ro 7-1986 were synthesized. The binding of these fluorescent ligands [BD 621 (I) and BD 607 (II)] to benzodiazepine receptors was characterized by direct fluorescence measurement. Both the equilibrium dissociation consts. (KD) of BD 621 and BD 607 and the maximum number of binding sites (Bmax) estimated by fluorescence monitoring were consistent with values obtained by using radioligand binding techniques. The binding of BD 621 and BD 607 assessed by fluorescence measurement was reversible, abolished by photoaffinity labeling with Ro 15-4513, and unaffected by a variety of substances that do not bind to benzodiazepine receptors. The potencies of chemical diverse benzodiazepine **receptor** compds. to inhibit fluorescent **ligand** binding were highly correlated with potencies obtained from radioligand binding techniques. These findings demonstrate the feasibility of using direct fluorescence measurement techniques to quantitate **ligand-receptor** interactions.

L13 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1986:105485 CAPLUS

DOCUMENT NUMBER: 104:105485
 TITLE: Mapping the turkey erythrocyte β - **receptor**
 : a distance geometry approach
 AUTHOR(S): Linschoten, Marcel R.; Bultsma, Teake; Ijzerman, Ad
 P.; Timmerman, Hendrik
 CORPORATE SOURCE: Dep. Pharmacochem., Free Univ., Amsterdam, 1081 HV,
 Neth.
 SOURCE: Journal of Medicinal Chemistry (1986), 29(2), 278-86
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Extensions and refinements of the **receptor** mapping method as originally developed by G. Crippen (1980) are presented. In a set of newly developed algorithms, measures are taken to reduce the number of required energy parameters to a statistically acceptable degree. The most important measure is the incorporation of lipophilicity as a hydrophobic bonding parameter to describe the binding of parts of the ligands to lipophilic areas on the **receptor**. To test the applicability of this set of programs, the turkey erythrocyte β **receptor** was mapped using a data set of J. P. Bilezikian et al. (1978). The exptl. determined free energies of binding can be reasonably described using a 9-point geometrical representation of the **receptor** site and only 6 energy parameters. The deduced model predicts that the Ph rings of phenylethanolamines and phenoxypropanolamines occupy different parts of the **receptor** site.

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	85.49	331.56
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-17.50	-29.40

FILE 'STNGUIDE' ENTERED AT 21:14:07 ON 23 SEP 2004
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
 AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Sep 17, 2004 (20040917/UP).

=> d his

(FILE 'HOME' ENTERED AT 20:38:41 ON 23 SEP 2004)

FILE 'REGISTRY' ENTERED AT 20:39:05 ON 23 SEP 2004

L1 STRUCTURE UPLOADED
 L2 50 S SAM L1
 L3 62637 S L1 FULL

FILE 'CAPLUS' ENTERED AT 20:48:04 ON 23 SEP 2004

L4 771 S L3 AND RECEPTOR
 L5 73 S L4 AND LIGAND
 L6 5 S L5 AND (DIVALENT OR MULTIVALENT OR DIMERIC OR MULTIMERIC OR M
 L7 12 S L4 AND G (3W) PROTEIN

FILE 'STNGUIDE' ENTERED AT 21:01:25 ON 23 SEP 2004

FILE 'CAPLUS' ENTERED AT 21:02:16 ON 23 SEP 2004


```

L8          10 S L4 AND MUSCARINIC
L9          68 S L5 NOT L6
L10         64 S L9 NOT L7
L11         61 S L10 NOT L8
L12         46 S L11 AND PY>1998
L13         15 S L11 NOT L12

```

FILE 'STNGUIDE' ENTERED AT 21:14:07 ON 23 SEP 2004

=> expand griffin j/au

'AU' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'STNGUIDE'
The indicated field code is not available for EXPAND in this
file. To see a list of valid EXPAND field codes, enter HELP
SFIELDS at an arrow prompt (=>).

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	1.68	333.24
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-29.40

FILE 'CAPLUS' ENTERED AT 21:31:08 ON 23 SEP 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Sep 2004 VOL 141 ISS 13

FILE LAST UPDATED: 22 Sep 2004 (20040922/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> expand griffin j/au

```

E1          4      GRIFFIN IVAN H/AU
E2          1      GRIFFIN IVAN J/AU
E3          59 --> GRIFFIN J/AU
E4          44      GRIFFIN J A/AU
E5          5      GRIFFIN J B/AU
E6          9      GRIFFIN J C/AU
E7          20      GRIFFIN J D/AU
E8          1      GRIFFIN J DENNIS/AU
E9          21      GRIFFIN J E/AU
E10         1      GRIFFIN J E E/AU
E11         1      GRIFFIN J E III/AU
E12        37      GRIFFIN J F/AU

```

=> s e3

L14 59 "GRIFFIN J"/AU

=> e griffin john/au

E1	19	GRIFFIN JOHANNA A/AU
E2	1	GRIFFIN JOHANNA ALLSTON/AU
E3	24 -->	GRIFFIN JOHN/AU
E4	2	GRIFFIN JOHN A/AU
E5	2	GRIFFIN JOHN B/AU
E6	6	GRIFFIN JOHN C/AU
E7	1	GRIFFIN JOHN C III/AU
E8	1	GRIFFIN JOHN CLARK/AU
E9	11	GRIFFIN JOHN D/AU
E10	1	GRIFFIN JOHN DOUGLAS/AU
E11	1	GRIFFIN JOHN FRANCIS THOMAS/AU
E12	1	GRIFFIN JOHN G/AU

=> s e3

L15 24 "GRIFFIN JOHN"/AU

=> s l14 or l15

L16 83 L14 OR L15

=> d his

(FILE 'HOME' ENTERED AT 20:38:41 ON 23 SEP 2004)

FILE 'REGISTRY' ENTERED AT 20:39:05 ON 23 SEP 2004

L1	STRUCTURE UPLOADED
L2	50 S SAM L1
L3	62637 S L1 FULL

FILE 'CAPLUS' ENTERED AT 20:48:04 ON 23 SEP 2004

L4	771 S L3 AND RECEPTOR
L5	73 S L4 AND LIGAND
L6	5 S L5 AND (Divalent OR MULTIVALENT OR DIMERIC OR MULTIMERIC OR M
L7	12 S L4 AND G (3W) PROTEIN

FILE 'STNGUIDE' ENTERED AT 21:01:25 ON 23 SEP 2004

FILE 'CAPLUS' ENTERED AT 21:02:16 ON 23 SEP 2004

L8	10 S L4 AND MUSCARINIC
L9	68 S L5 NOT L6
L10	64 S L9 NOT L7
L11	61 S L10 NOT L8
L12	46 S L11 AND PY>1998
L13	15 S L11 NOT L12

FILE 'STNGUIDE' ENTERED AT 21:14:07 ON 23 SEP 2004

FILE 'CAPLUS' ENTERED AT 21:31:08 ON 23 SEP 2004

	EXPAND GRIFFIN J/AU
L14	59 S E3
	E GRIFFIN JOHN/AU
L15	24 S E3
L16	83 S L14 OR L15

=> s l4 and l16

L17 0 L4 AND L16

=> s l3 and l16

	23107 L3
L18	0 L3 AND L16

=> d his

(FILE 'HOME' ENTERED AT 20:38:41 ON 23 SEP 2004)

FILE 'REGISTRY' ENTERED AT 20:39:05 ON 23 SEP 2004

L1 STRUCTURE UPLOADED
L2 50 S SAM L1
L3 62637 S L1 FULL

FILE 'CAPLUS' ENTERED AT 20:48:04 ON 23 SEP 2004

L4 771 S L3 AND RECEPTOR
L5 73 S L4 AND LIGAND
L6 5 S L5 AND (DIVALENT OR MULTIVALENT OR DIMERIC OR MULTIMERIC OR M
L7 12 S L4 AND G (3W) PROTEIN

FILE 'STNGUIDE' ENTERED AT 21:01:25 ON 23 SEP 2004

FILE 'CAPLUS' ENTERED AT 21:02:16 ON 23 SEP 2004

L8 10 S L4 AND MUSCARINIC
L9 68 S L5 NOT L6
L10 64 S L9 NOT L7
L11 61 S L10 NOT L8
L12 46 S L11 AND PY>1998
L13 15 S L11 NOT L12

FILE 'STNGUIDE' ENTERED AT 21:14:07 ON 23 SEP 2004

FILE 'CAPLUS' ENTERED AT 21:31:08 ON 23 SEP 2004

EXPAND GRIFFIN J/AU
L14 59 S E3
E GRIFFIN JOHN/AU
L15 24 S E3
L16 83 S L14 OR L15
L17 0 S L4 AND L16
L18 0 S L3 AND L16

=> logoff y
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
5.84	339.08

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-29.40

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 21:34:09 ON 23 SEP 2004